DE69231345T2 - Oberflächenmodifizierte Arzneimittel-Nanopartikel - Google Patents

Oberflächenmodifizierte Arzneimittel-Nanopartikel

Info

Publication number
DE69231345T2
DE69231345T2 DE69231345T DE69231345T DE69231345T2 DE 69231345 T2 DE69231345 T2 DE 69231345T2 DE 69231345 T DE69231345 T DE 69231345T DE 69231345 T DE69231345 T DE 69231345T DE 69231345 T2 DE69231345 T2 DE 69231345T2
Authority
DE
Germany
Prior art keywords
particles
surface modified
methods
modified drug
drug nanoparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69231345T
Other languages
English (en)
Other versions
DE69231345D1 (de
Inventor
Gary Liversidge
Kenneth Cundy
John Bishop
David Czekai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanosystems LLC
Original Assignee
Nanosystems LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24595721&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69231345(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nanosystems LLC filed Critical Nanosystems LLC
Publication of DE69231345D1 publication Critical patent/DE69231345D1/de
Application granted granted Critical
Publication of DE69231345T2 publication Critical patent/DE69231345T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0476—Particles, beads, capsules, spheres
    • A61K49/0485—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
    • A61K49/049—Surface-modified nanoparticles, e.g. immune-nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414—Particles, beads, capsules or spheres
    • A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414—Particles, beads, capsules or spheres
    • A61K49/0423—Nanoparticles, nanobeads, nanospheres, nanocapsules, i.e. having a size or diameter smaller than 1 micrometer
    • A61K49/0428—Surface-modified nanoparticles, e.g. immuno-nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
DE69231345T 1991-01-25 1992-01-20 Oberflächenmodifizierte Arzneimittel-Nanopartikel Revoked DE69231345T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/647,105 US5145684A (en) 1991-01-25 1991-01-25 Surface modified drug nanoparticles

Publications (2)

Publication Number Publication Date
DE69231345D1 DE69231345D1 (de) 2000-09-21
DE69231345T2 true DE69231345T2 (de) 2001-04-26

Family

ID=24595721

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69231345T Revoked DE69231345T2 (de) 1991-01-25 1992-01-20 Oberflächenmodifizierte Arzneimittel-Nanopartikel

Country Status (22)

Country Link
US (1) US5145684A (de)
EP (1) EP0499299B1 (de)
JP (1) JP3602546B2 (de)
KR (1) KR100200061B1 (de)
AT (1) ATE195416T1 (de)
CA (1) CA2059432C (de)
DE (1) DE69231345T2 (de)
DK (1) DK0499299T3 (de)
ES (1) ES2149164T3 (de)
FI (1) FI108333B (de)
GR (1) GR3034759T3 (de)
HU (1) HU221586B (de)
IE (1) IE920217A1 (de)
IL (1) IL100754A (de)
MX (1) MX9200291A (de)
MY (1) MY108134A (de)
NO (1) NO303668B1 (de)
NZ (1) NZ241362A (de)
PT (1) PT499299E (de)
RU (1) RU2066553C1 (de)
SG (1) SG55104A1 (de)
TW (1) TW247275B (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102018103528A1 (de) 2018-02-16 2019-08-22 Friedrich-Alexander-Universität Erlangen-Nürnberg Suspension nanoskaliger, organischer Partikel und Verfahren zu ihrer Herstellung

Families Citing this family (1181)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994041A (en) * 1985-04-06 1999-11-30 Eastman Kodak Company Process for buffering concentrated aqueous slurries
US5552154A (en) 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
SE9101090D0 (sv) * 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
US5766635A (en) * 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5407659A (en) * 1991-10-22 1995-04-18 Mallinckrodt Medical, Inc. Treated calcium/oxyanion-containing particles for medical diagnostic imaging
US5344640A (en) * 1991-10-22 1994-09-06 Mallinckrodt Medical, Inc. Preparation of apatite particles for medical diagnostic imaging
US5342609A (en) * 1991-10-22 1994-08-30 Mallinckrodt Medical, Inc. Microfluidization of calcium/oxyanion-containing particles
US5916540A (en) * 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
NZ246421A (en) * 1991-12-18 1996-05-28 Minnesota Mining & Mfg Aerosol formulation containing a drug and a propellant and which is substantially free of surfactant
US6080751A (en) * 1992-01-14 2000-06-27 The Stehlin Foundation For Cancer Research Method for treating pancreatic cancer in humans with water-insoluble S-camptothecin of the closed lactone ring form and derivatives thereof
DK0644755T3 (da) * 1992-06-10 1997-09-22 Nanosystems Llc Overflademodificerede NSAID-nanopartikler
US5552156A (en) * 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
AU660852B2 (en) * 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) * 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) * 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5364550A (en) * 1992-12-16 1994-11-15 Eastman Kodak Company Liquid detergent composition
US5352459A (en) * 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5256328A (en) * 1992-12-16 1993-10-26 Eastman Kodak Company Liquid toilet bowl cleaner and sanitizer containing halogen donating nanoparticles
US5322679A (en) * 1992-12-16 1994-06-21 Sterling Winthrop Inc. Iodinated aroyloxy esters
US5326552A (en) * 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
US5354564A (en) * 1992-12-18 1994-10-11 Eastman Kodak Company Personal care compositions
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
FR2702160B1 (fr) * 1993-03-02 1995-06-02 Biovecteurs As Vecteurs particulaires synthétiques et procédé de préparation.
US5840277A (en) * 1993-03-30 1998-11-24 Charlotte Hospital Authority Treatment of chronic pulmonary inflammation
US5849263A (en) * 1993-03-30 1998-12-15 Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
US5830436A (en) * 1993-03-30 1998-11-03 Duke University Method of mucociliary clearance in cystic fibrosis patients using alkylaryl polyether alcohol polymers
CH686761A5 (de) 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
US5543158A (en) * 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5635206A (en) * 1994-01-20 1997-06-03 Hoffmann-La Roche Inc. Process for liposomes or proliposomes
EP0678771B1 (de) * 1994-04-18 2001-11-21 Eastman Kodak Company Stabile wässrige Festpartikeldispersionen
US5468598A (en) * 1994-04-18 1995-11-21 Eastman Kodak Company Solid particle dispersions for imaging systems
US5478705A (en) * 1994-05-25 1995-12-26 Eastman Kodak Company Milling a compound useful in imaging elements using polymeric milling media
US5500331A (en) * 1994-05-25 1996-03-19 Eastman Kodak Company Comminution with small particle milling media
US5513803A (en) * 1994-05-25 1996-05-07 Eastman Kodak Company Continuous media recirculation milling process
TW384224B (en) * 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5587143A (en) * 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US6007845A (en) * 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US20110196039A9 (en) * 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US5955108A (en) * 1994-12-16 1999-09-21 Quadrant Healthcare (Uk) Limited Cross-linked microparticles and their use as therapeutic vehicles
US6524557B1 (en) * 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US5609998A (en) * 1994-12-29 1997-03-11 Eastman Kodak Company Process for dispersing concentrated aqueous slurries
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
US5585108A (en) * 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5466440A (en) * 1994-12-30 1995-11-14 Eastman Kodak Company Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays
US5628981A (en) * 1994-12-30 1997-05-13 Nano Systems L.L.C. Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
US5560932A (en) * 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5665331A (en) * 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5716642A (en) * 1995-01-10 1998-02-10 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents
US5662883A (en) * 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5569448A (en) * 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5520904A (en) * 1995-01-27 1996-05-28 Mallinckrodt Medical, Inc. Calcium/oxyanion-containing particles with a polymerical alkoxy coating for use in medical diagnostic imaging
WO1996024332A1 (en) * 1995-02-06 1996-08-15 Nanosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5571536A (en) * 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5503723A (en) * 1995-02-08 1996-04-02 Eastman Kodak Company Isolation of ultra small particles
US5665330A (en) * 1995-02-08 1997-09-09 Nano Systems Llc Dual purposed diagnostic/therapeutic agent having a tri-iodinated benzoyl group linked to a coumarin
US5622938A (en) * 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5518738A (en) * 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5591456A (en) * 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) * 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
WO1996025181A1 (en) * 1995-02-14 1996-08-22 Nanosystems L.L.C. Process of preparing lymphography contrast agents
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5543133A (en) * 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5580579A (en) * 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
WO1996025918A1 (en) * 1995-02-24 1996-08-29 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
US5565188A (en) * 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5736156A (en) * 1995-03-22 1998-04-07 The Ohio State University Liposomal anf micellular stabilization of camptothecin drugs
US5605696A (en) * 1995-03-30 1997-02-25 Advanced Cardiovascular Systems, Inc. Drug loaded polymeric material and method of manufacture
US6428771B1 (en) * 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
IL118088A0 (en) * 1995-06-07 1996-08-04 Anzon Inc Colloidal particles of solid flame retardant and smoke suppressant compounds and methods for making them
ES2177592T3 (es) * 1995-07-05 2002-12-16 Europ Economic Community Nanoparticulas biocompatibles y biodegradables para la absorcion y administracion de medicamentos proteinicos.
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US6290969B1 (en) * 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6592877B1 (en) * 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6391338B1 (en) * 1995-09-07 2002-05-21 Biovail Technologies Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
US5834025A (en) 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
CA2234957C (en) * 1995-10-17 2006-12-19 Inge B. Henriksen Insoluble drug delivery
US5679138A (en) * 1995-11-30 1997-10-21 Eastman Kodak Company Ink jet inks containing nanoparticles of organic pigments
US5662279A (en) * 1995-12-05 1997-09-02 Eastman Kodak Company Process for milling and media separation
US20050267302A1 (en) * 1995-12-11 2005-12-01 G.D. Searle & Co. Eplerenone crystalline form exhibiting enhanced dissolution rate
US5968543A (en) * 1996-01-05 1999-10-19 Advanced Polymer Systems, Inc. Polymers with controlled physical state and bioerodibility
US5686133A (en) * 1996-01-31 1997-11-11 Port Systems, L.L.C. Water soluble pharmaceutical coating and method for producing coated pharmaceuticals
DK0904113T3 (da) * 1996-03-05 2004-08-30 Acusphere Inc Mikroindkapslede fluorerede gasser til anvendelse som billeddannende midler
US5611344A (en) * 1996-03-05 1997-03-18 Acusphere, Inc. Microencapsulated fluorinated gases for use as imaging agents
WO1997044015A1 (en) * 1996-05-17 1997-11-27 Andaris Limited Microparticles and their use in wound therapy
US6652837B1 (en) * 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
US20020052310A1 (en) * 1997-09-15 2002-05-02 Massachusetts Institute Of Technology The Penn State Research Foundation Particles for inhalation having sustained release properties
US6254854B1 (en) * 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US6503480B1 (en) 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
USRE37053E1 (en) 1996-05-24 2001-02-13 Massachusetts Institute Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
ATE302599T1 (de) * 1996-05-24 2005-09-15 Angiotech Pharm Inc Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege
US5726154A (en) * 1996-06-28 1998-03-10 University Of Utah Research Foundation Stabilization and oral delivery of calcitonin
US5837221A (en) * 1996-07-29 1998-11-17 Acusphere, Inc. Polymer-lipid microencapsulated gases for use as imaging agents
US5935890A (en) 1996-08-01 1999-08-10 Glcc Technologies, Inc. Stable dispersions of metal passivation agents and methods for making them
US7255877B2 (en) * 1996-08-22 2007-08-14 Jagotec Ag Fenofibrate microparticles
US6465016B2 (en) 1996-08-22 2002-10-15 Research Triangle Pharmaceuticals Cyclosporiine particles
US7060253B1 (en) * 1996-09-20 2006-06-13 Mundschenk David D Topical formulations and delivery systems
GB9622173D0 (en) * 1996-10-24 1996-12-18 Glaxo Group Ltd Particulate Products
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US5993856A (en) * 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
US6416778B1 (en) * 1997-01-24 2002-07-09 Femmepharma Pharmaceutical preparations and methods for their regional administration
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
WO1998035666A1 (en) * 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
CO4920215A1 (es) * 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
US20050004049A1 (en) * 1997-03-11 2005-01-06 Elan Pharma International Limited Novel griseofulvin compositions
US5989591A (en) * 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
US6193954B1 (en) * 1997-03-21 2001-02-27 Abbott Laboratories Formulations for pulmonary delivery of dopamine agonists
AU7133898A (en) * 1997-04-18 1998-11-13 Vertex Pharmaceuticals Incorporated Nanosized aspartyl protease inhibitors
CA2288789C (en) 1997-05-08 2009-07-21 Merck Sharp & Dohme Limited Substituted 1,2,4-triazolo[3,4-a]phthalazine derivatives as gaba alpha 5 ligands
IT1292142B1 (it) * 1997-06-12 1999-01-25 Maria Rosa Gasco Composizione farmaceutica in forma di microparticelle lipidiche solide atte alla somministrazione parenterale
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
IL133672A0 (en) * 1997-06-27 2001-04-30 Vivorx Pharmaceuticals Inc Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
EP3266450A1 (de) 1997-06-27 2018-01-10 Abraxis BioScience, LLC Neuartige formulierungen von pharmakologischen wirkstoffen, verfahren zur herstellung davon und verfahren zur verwendung davon
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6946117B1 (en) * 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
US6919070B1 (en) * 1997-10-17 2005-07-19 Zakrytoe Aktsionernoe Obschestvo “OSTIM” Stomatic composition
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
GB9726543D0 (en) * 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel compositions
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
BR9908155A (pt) 1998-02-25 2000-10-31 Merck Sharp & Dohme Composto, composição farmacêutica, uso do composto, e, processo para intensificar cognição em um sujeito sofrendo de cognição diminuìda
ZA991922B (en) * 1998-03-11 1999-09-13 Smithkline Beecham Corp Novel compositions of eprosartan.
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6337092B1 (en) 1998-03-30 2002-01-08 Rtp Pharma Inc. Composition and method of preparing microparticles of water-insoluble substances
ES2257041T3 (es) * 1998-03-30 2006-07-16 Jagotec Ag Composicion y metodo para preparar microparticulas de substancias insolubles en agua.
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
DE69914742T2 (de) 1998-05-29 2004-11-25 Skyepharma Canada Inc., Verdun Gegen hitzeeinwirkung geschützte mikropartikel und verfahren zur terminalen dampfsterilisation derselben
US6153225A (en) * 1998-08-13 2000-11-28 Elan Pharma International Limited Injectable formulations of nanoparticulate naproxen
US6956021B1 (en) 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
US6165506A (en) * 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20080213378A1 (en) * 1998-10-01 2008-09-04 Elan Pharma International, Ltd. Nanoparticulate statin formulations and novel statin combinations
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
WO2000018374A1 (en) * 1998-10-01 2000-04-06 Elan Pharma International, Ltd. Controlled release nanoparticulate compositions
US20070160675A1 (en) * 1998-11-02 2007-07-12 Elan Corporation, Plc Nanoparticulate and controlled release compositions comprising a cephalosporin
DK1126826T6 (en) * 1998-11-02 2019-06-24 Alkermes Pharma Ireland Ltd Multiparticulate modified release of methylphenidate
US20090297602A1 (en) * 1998-11-02 2009-12-03 Devane John G Modified Release Loxoprofen Compositions
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6375986B1 (en) 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
GB9824897D0 (en) 1998-11-12 1999-01-06 Merck Sharp & Dohme Therapeutic compounds
US6969529B2 (en) * 2000-09-21 2005-11-29 Elan Pharma International Ltd. Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
SI1131070T1 (sl) * 1998-11-12 2008-12-31 Smithkline Beecham Plc Farmacevtski sestavek za modificirano sproĺ äśanje senzibilizatorja za inzulin in metformina
ID29270A (id) 1998-11-20 2001-08-16 Rtp Pharma Inc Partikel-partikel mikro yang distabilkan oleh fosfolipid yang dapat menyebar
US6395511B1 (en) * 1998-11-27 2002-05-28 Darwin Discovery, Ltd. Nucleic acids encoding a novel family of TGF-β binding proteins from humans
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
DE19856432A1 (de) * 1998-12-08 2000-06-15 Basf Ag Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
ATE216875T1 (de) 1999-01-27 2002-05-15 Idea Ag Nichtinvasive impfung durch die haut
DK1031347T3 (da) 1999-01-27 2002-07-08 Idea Ag Transnasal transport/immunisering med meget tilpasselige bærere
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6270806B1 (en) 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US6267989B1 (en) * 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
EG23951A (en) 1999-03-25 2008-01-29 Otsuka Pharma Co Ltd Cilostazol preparation
US6383471B1 (en) 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US8143386B2 (en) * 1999-04-07 2012-03-27 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
WO2000060940A1 (en) * 1999-04-12 2000-10-19 Dow Agrosciences Llc Aqueous dispersions of agricultural chemicals
US6309749B1 (en) 1999-05-06 2001-10-30 Eastman Kodak Company Ceramic milling media containing tetragonal zirconia
US6491239B2 (en) 1999-05-06 2002-12-10 Eastman Kodak Company Process for milling compounds
US6444223B1 (en) 1999-05-28 2002-09-03 Alkermes Controlled Therapeutics, Inc. Method of producing submicron particles of a labile agent and use thereof
WO2000072973A1 (en) * 1999-06-01 2000-12-07 Elan Pharma International Ltd. Small-scale mill and method thereof
US20090104273A1 (en) * 1999-06-22 2009-04-23 Elan Pharma International Ltd. Novel nifedipine compositions
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
AU779986B2 (en) 1999-06-29 2005-02-24 Mannkind Corporation Purification and stabilization of peptide and protein pharmaceutical agents
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6458383B2 (en) 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US6982281B1 (en) * 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
MXPA02000053A (es) * 1999-07-05 2003-07-21 Idea Ag Un metodo para mejorar el tratamiento a traves de barreras adaptables semipermeables.
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
FR2795961B1 (fr) 1999-07-09 2004-05-28 Ethypharm Lab Prod Ethiques Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
US7863331B2 (en) * 1999-07-09 2011-01-04 Ethypharm Pharmaceutical composition containing fenofibrate and method for the preparation thereof
US6933318B1 (en) 1999-08-12 2005-08-23 Eli Lilly And Company Topical organic ectoparasiticidal formulations
IL147828A0 (en) 1999-08-12 2002-08-14 Lilly Co Eli Oral treatment of companion animals with ectoparasiticidal spinosyns
US6927210B1 (en) 1999-08-12 2005-08-09 Eli Lilly And Company Ectoparasiticidal aqueous suspension formulations of spinosyns
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US20010036481A1 (en) * 1999-08-25 2001-11-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
WO2001013891A2 (en) * 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US6656504B1 (en) 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
WO2001024820A1 (en) * 1999-10-07 2001-04-12 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
NZ529928A (en) 1999-10-29 2005-10-28 Euro Celtique Sa Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
US20030096798A1 (en) * 1999-11-09 2003-05-22 Williams Gordon H. Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
US20030203884A1 (en) * 1999-11-09 2003-10-30 Pharmacia Corporation Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
AUPQ441699A0 (en) 1999-12-02 2000-01-06 Eli Lilly And Company Pour-on formulations
US20030083493A1 (en) * 1999-12-08 2003-05-01 Barton Kathleen P. Eplerenone drug substance having high phase purity
US6251136B1 (en) 1999-12-08 2001-06-26 Advanced Cardiovascular Systems, Inc. Method of layering a three-coated stent using pharmacological and polymeric agents
SK12672001A3 (sk) * 1999-12-08 2002-04-04 Pharmacia Corporation Zloženia inhibítora cyklooxygenázy-2 s rýchlym nástupom terapeutického účinku
EA008449B1 (ru) * 1999-12-08 2007-06-29 Фармация Корпорейшн Кристаллическая форма эплеренона
UA74539C2 (en) 1999-12-08 2006-01-16 Pharmacia Corp Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
US6702849B1 (en) 1999-12-13 2004-03-09 Advanced Cardiovascular Systems, Inc. Method of processing open-celled microcellular polymeric foams with controlled porosity for use as vascular grafts and stent covers
US8771740B2 (en) * 1999-12-20 2014-07-08 Nicholas J. Kerkhof Process for producing nanoparticles by spray drying
WO2001045674A1 (en) 1999-12-20 2001-06-28 Cocensys, Inc. Process for producing nanometer particles by fluid bed spray-drying
JP2003518485A (ja) 1999-12-23 2003-06-10 ファイザー・プロダクツ・インク 向上された薬物濃度を与える医薬組成物
GB9930562D0 (en) * 1999-12-23 2000-02-16 Boc Group Plc Partial oxidation of hydrogen sulphide
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
EP1253903B1 (de) 2000-01-31 2006-05-17 Engelhard Corporation Tensidfreietopische zusammensetzungen und verfahren zur schnelle herstellung davon
IL151097A0 (en) 2000-02-23 2003-04-10 Smithkline Beecham Biolog Tumour-specific animal proteins
AU2001241738A1 (en) * 2000-02-25 2001-09-03 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
AU4724401A (en) * 2000-02-28 2001-09-12 Genesegues Inc Nanocapsule encapsulation system and method
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
AUPQ634300A0 (en) * 2000-03-20 2000-04-15 Eli Lilly And Company Synergistic formulations
US7153525B1 (en) * 2000-03-22 2006-12-26 The University Of Kentucky Research Foundation Microemulsions as precursors to solid nanoparticles
ATE343562T1 (de) 2000-03-23 2006-11-15 Elan Pharm Inc Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
GB0009773D0 (en) * 2000-04-19 2000-06-07 Univ Cardiff Particulate composition
US6682761B2 (en) 2000-04-20 2004-01-27 Rtp Pharma, Inc. Water-insoluble drug particle process
AU5967101A (en) 2000-05-10 2001-11-20 Rtp Pharma Inc Media milling
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
AU6124601A (en) 2000-05-10 2001-11-20 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
US20040156872A1 (en) * 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
MY120279A (en) * 2000-05-26 2005-09-30 Pharmacia Corp Use of a celecoxib composition for fast pain relief
ATE442866T1 (de) * 2000-06-20 2009-10-15 Corixa Corp Fusionsproteine aus mycobakterium tuberculosis
US6849713B2 (en) * 2000-06-27 2005-02-01 Genelabs Technologies, Inc. Compounds possessing antibacterial, antifungal or antitumor activity
JP2004513615A (ja) 2000-06-28 2004-05-13 コリクサ　コーポレイション 肺癌の治療および診断のための組成物および方法
EP1666452A2 (de) 2000-06-30 2006-06-07 Elan Pharmaceuticals, Inc. Verbindungen zur Behandlung der Alzheimerischen Krankheit
US6846813B2 (en) * 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
US20030096864A1 (en) * 2000-06-30 2003-05-22 Fang Lawrence Y. Compounds to treat alzheimer's disease
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
CN1217920C (zh) 2000-06-30 2005-09-07 艾兰制药公司 治疗早老性痴呆的化合物
IN192160B (de) * 2000-07-17 2004-02-28 Ranbaxy Lab
US6656505B2 (en) * 2000-07-21 2003-12-02 Alpharma Uspd Inc. Method for forming an aqueous flocculated suspension
US20020123485A1 (en) * 2000-07-27 2002-09-05 Alexander John C. Epoxy steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure
US6716829B2 (en) 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
CA2419256A1 (en) * 2000-08-28 2002-03-07 Kenton N. Fedde Use of an aldosterone receptor antagonist to improve cognitive function
AU8847101A (en) 2000-08-31 2002-03-13 Rtp Pharma Inc Milled particles
US8586094B2 (en) 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
US7276249B2 (en) * 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
US7998507B2 (en) * 2000-09-21 2011-08-16 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
US7198795B2 (en) * 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
US20080241070A1 (en) * 2000-09-21 2008-10-02 Elan Pharma International Ltd. Fenofibrate dosage forms
US20030224058A1 (en) * 2002-05-24 2003-12-04 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
KR101045144B1 (ko) 2000-10-30 2011-06-30 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US6756062B2 (en) 2000-11-03 2004-06-29 Board Of Regents University Of Texas System Preparation of drug particles using evaporation precipitation into aqueous solutions
US8551526B2 (en) * 2000-11-03 2013-10-08 Board Of Regents, The University Of Texas System Preparation of drug particles using evaporation precipitation into aqueous solutions
US20030198679A1 (en) * 2000-11-08 2003-10-23 Kundu Subhas C. Flocculated pharmaceutical suspensions and methods for actives
CA2427467C (en) * 2000-11-09 2010-01-12 Neopharm, Inc. Sn-38 lipid complexes and methods of use
GB0028583D0 (en) * 2000-11-23 2001-01-10 Merck Sharp & Dohme Therapeutic compounds
EP2168571B1 (de) 2000-11-30 2018-08-22 Vectura Limited Inhalierbare Arzneizusammensetzung
EP1920763B2 (de) 2000-11-30 2022-06-15 Vectura Limited Pharmazeutische Zusammensetzungen zur Inhalation
WO2002045691A2 (en) * 2000-12-06 2002-06-13 Pharmacia Corporation Laboratory scale milling process
HUP0400683A2 (hu) * 2000-12-11 2004-06-28 Takeda Chemical Industries, Ltd. HER2 inhibitort tartalmazó fokozott felszívódású gyógyászati készítmény
DE10063090A1 (de) * 2000-12-18 2002-06-20 Henkel Kgaa Nanoskaliges ZnO in Hygiene-Produkten
DE10063092A1 (de) * 2000-12-18 2002-06-20 Henkel Kgaa Nanoskalige Materialien in Hygiene-Produkten
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US6623761B2 (en) 2000-12-22 2003-09-23 Hassan Emadeldin M. Method of making nanoparticles of substantially water insoluble materials
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US8067032B2 (en) * 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US7037528B2 (en) * 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
DK1347747T3 (da) * 2000-12-22 2006-04-10 Baxter Int Fremgangsmåde til behandling af submikropartikelsuspensioner af farmaceutiske midler
US20020198254A1 (en) * 2000-12-27 2002-12-26 Velligan Mark D. Polyamide analogs
US20020141946A1 (en) * 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
EP1345629A2 (de) 2000-12-29 2003-09-24 Advanced Inhalation Research, Inc. Inhalationspartikel mit verzögerter freigabe
US20030125236A1 (en) * 2000-12-29 2003-07-03 Advenced Inhalation Research, Inc. Particles for inhalation having rapid release properties
FI20010115A0 (fi) * 2001-01-18 2001-01-18 Orion Corp Menetelmä nanopartikkelien valmistamiseksi
US20030053981A1 (en) * 2001-01-26 2003-03-20 Schering Corporation Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
CZ20032031A3 (cs) * 2001-01-26 2003-12-17 Schering Corporation Farmaceutický prostředek
RS51449B (sr) * 2001-01-26 2011-04-30 Schering Corporation Kombinacija aktivatora peroksizom proliferator-aktiviranog receptora (ppar) i inhibitora apsorpcije sterola i lečenje vaskularnih indikacija
CA2434430A1 (en) * 2001-01-26 2002-08-01 Harry R. Davis The use of substituted azetidinone compounds for the treatment of sitosterolemia
TW200840563A (en) * 2001-01-26 2008-10-16 Schering Corp Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(S) and treatments for vascular indications
NZ542090A (en) * 2001-01-26 2006-09-29 Schering Corp Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
CA2436418A1 (en) * 2001-01-30 2002-08-08 Board Of Regents, The University Of Texas Systems Process for production of nanoparticles and microparticles by spray freezing into liquid
US20040022861A1 (en) * 2001-01-30 2004-02-05 Williams Robert O. Process for production of nanoparticles and microparticles by spray freezing into liquid
US6509027B2 (en) 2001-02-12 2003-01-21 Supergen, Inc. Injectable pharmaceutical composition comprising coated particles of camptothecin
US6497896B2 (en) 2001-02-12 2002-12-24 Supergen, Inc. Method for administering camptothecins via injection of a pharmaceutical composition comprising microdroplets containing a camptothecin
US20020150615A1 (en) * 2001-02-12 2002-10-17 Howard Sands Injectable pharmaceutical composition comprising microdroplets of a camptothecin
JP3386052B2 (ja) * 2001-02-13 2003-03-10 トヨタ自動車株式会社 ポンプ装置
ES2275866T3 (es) 2001-02-14 2007-06-16 Tibotec Pharmaceuticals Ltd. 2-(aminosustituido)-benzotiazol-sulfonamidas de amplio esprecto inhibidoras de la proteasa de vih.
CN1273112C (zh) * 2001-02-22 2006-09-06 斯凯伊药品加拿大公司 具有减少进食－禁食作用的贝特－它汀组合
BR0208626A (pt) * 2001-04-03 2004-03-09 Schering Corp Composição antifúngica com biodisponibilidade intensificada
AU2002245979A1 (en) * 2001-04-05 2002-10-21 Universite Laval Process for making protein delivery matrix and uses thereof
PL367084A1 (en) 2001-04-09 2005-02-21 Tibotec Pharmaceuticals Ltd. Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide hiv protease inhibitors
US20040126900A1 (en) * 2001-04-13 2004-07-01 Barry Stephen E High affinity peptide- containing nanoparticles
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
CA2445763A1 (en) * 2001-05-01 2002-11-07 Angiotech Pharmaceuticals Inc. Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions
US20030157161A1 (en) * 2001-05-01 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
ITMO20010086A1 (it) * 2001-05-08 2002-11-08 Worgas Bruciatori Srl Metodo ed apparato per ridurre le emissioni di biossido di azoto (no2)in un apparecchio da riscaldamento senza canna fumaria
WO2002089747A2 (en) 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
CN100549007C (zh) 2001-05-11 2009-10-14 泰博特克药品有限公司 广谱2-氨基-苯并唑磺酰胺hiv蛋白酶抑制剂
DE10125290B4 (de) * 2001-05-15 2005-04-14 Siemens Ag Verfahren zum Aufbereiten von Nano-Dispersanten
EP1392440A2 (de) * 2001-05-23 2004-03-03 E.I. Du Pont De Nemours And Company Hochdruckmühle mit mahlkörpern
US20030013699A1 (en) * 2001-05-25 2003-01-16 Davis Harry R. Methods for treating alzheimer's disease and/or regulating levels of amyloid beta peptides in a subject
WO2003030864A1 (en) * 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
US6976647B2 (en) * 2001-06-05 2005-12-20 Elan Pharma International, Limited System and method for milling materials
CA2449490C (en) * 2001-06-05 2010-10-05 Elan Pharma International Limited System and method for milling materials
US6730319B2 (en) 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
US20040173147A1 (en) * 2001-06-07 2004-09-09 Figueroa Iddys D. Application of a bioactive agent to a delivery substrate
US20040173146A1 (en) * 2001-06-07 2004-09-09 Figueroa Iddys D. Application of a bioactive agent to a delivery substrate
US6962715B2 (en) * 2001-10-24 2005-11-08 Hewlett-Packard Development Company, L.P. Method and dosage form for dispensing a bioactive substance
CA2450205A1 (en) 2001-06-13 2002-12-19 Elan Pharmaceuticals, Inc. Aminediols for the treatment of alzheimer's disease
GB0114532D0 (en) * 2001-06-14 2001-08-08 Jagotec Ag Novel compositions
JP2005504266A (ja) * 2001-06-22 2005-02-10 エラン ファーマ インターナショナル，リミティド 小規模ミルまたは微小流体工学を用いる高スループットスクリーニング法
EP1269994A3 (de) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten
EP1401399A2 (de) * 2001-06-22 2004-03-31 Pfizer Products Inc. Pharmzeutische zubereitungen enthaltend anlagerungsprodukte aus polymer und wirkstoff
US7758890B2 (en) 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
MXPA04000140A (es) * 2001-06-27 2004-06-03 Elan Pharm Inc Derivados de beta-hidroxiamina utiles en el tratamiento de enfermedad de alzheimer.
WO2003006013A1 (en) * 2001-07-10 2003-01-23 Elan Pharmaceuticals, Inc. Diaminediols for the treatment of alzheimer's disease
MXPA04000337A (es) * 2001-07-10 2004-07-23 Upjohn Co Amindioles para tratamiento de enfermedad de alzheimer.
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
US20030220310A1 (en) * 2001-07-27 2003-11-27 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
US20080305173A1 (en) * 2001-07-31 2008-12-11 Beuford Arlie Bogue Amorphous drug beads
ES2287293T3 (es) * 2001-08-06 2007-12-16 Astrazeneca Ab Dispersion acuosa que comprende nanoparticulas estables de trigliceridos de cadena media (mct) activos, insolubles en agua y de tipo excipiente.
GB0119480D0 (en) * 2001-08-09 2001-10-03 Jagotec Ag Novel compositions
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
DE60214012T2 (de) * 2001-08-29 2006-12-21 Dow Global Technologies, Inc., Midland Verfahren zur herstellung kristalliner arzneimittelteilchen durch ausfällung
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
EP2347654B1 (de) * 2001-09-17 2019-02-27 Elanco US Inc. Zusammensetzung zur Bekämpfung von Läusen und Zecken in Vieh
DE60217367T2 (de) * 2001-09-19 2007-10-18 Elan Pharma International Ltd. Nanopartikelzusammensetzungen enthaltend insulin
DE60216300T2 (de) * 2001-09-21 2007-06-28 Schering Corp. Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
CN1556700A (zh) * 2001-09-21 2004-12-22 ���鹫˾ 使用甾醇吸收抑制剂治疗或预防脉管炎的方法
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
JP2005529060A (ja) * 2001-09-25 2005-09-29 ファルマシア コーポレイション Ｎ−（２−ヒドロキシアセチル）−５−（４−ピペリヂル）−４−（４−ピリミヂニル）−３−（４−クロロフェニル）ピラゾールの固体形態
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
CA2461349C (en) 2001-09-26 2011-11-29 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US7544681B2 (en) * 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
US20050191359A1 (en) * 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
US20050227911A1 (en) * 2001-09-28 2005-10-13 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules
US6878693B2 (en) * 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
US20050233003A1 (en) * 2001-09-28 2005-10-20 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid
WO2003029169A2 (en) 2001-10-04 2003-04-10 Elan Pharmaceuticals, Inc. Hydroxypropylamines
JP2005508939A (ja) * 2001-10-12 2005-04-07 エラン ファーマ インターナショナル，リミティド 即時放出および徐放特性を組み合わせて有する組成物
ES2625340T3 (es) * 2001-10-15 2017-07-19 Crititech, Inc. Composiciones y métodos para la administración de fármacos escasamente solubles en agua y métodos de tratamiento
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
TWI330183B (de) * 2001-10-22 2010-09-11 Eisai R&D Man Co Ltd
JP2005519657A (ja) * 2001-11-07 2005-07-07 インコール ファーマシューティカル カンパニー ナノ微粒子造影剤を用いた血管撮像の方法
AP2004003049A0 (en) * 2001-11-08 2004-06-30 Elan Pharm Inc N,N' -substituted-1,3-diamino -2-hydroxypropane derivatives.
US7700851B2 (en) * 2001-11-13 2010-04-20 U.S. Smokeless Tobacco Company Tobacco nicotine demethylase genomic clone and uses thereof
CA2467476A1 (en) * 2001-11-19 2003-05-30 Pharmacia & Upjohn Company Amino diols useful in the treatment of alzheimer's disease
US20030129250A1 (en) * 2001-11-20 2003-07-10 Advanced Inhalation Research Inc. Particulate compositions for improving solubility of poorly soluble agents
PT1455755E (pt) * 2001-11-20 2013-06-18 Civitas Therapeutics Inc Composições particuladas melhoradas para distribuição pulmonar
GB0127805D0 (en) * 2001-11-20 2002-01-09 Smithkline Beecham Plc Pharmaceutical composition
UA76810C2 (uk) * 2001-12-10 2006-09-15 Мерк Енд Ко., Інк. Фармацевтична композиція антагоніста рецептора тахікініну у формі наночастинок
CA2476755C (en) 2001-12-17 2014-08-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
JP2005514393A (ja) 2001-12-19 2005-05-19 ネクター セラピューティクス アミノグリコシドの肺への供給
MXPA04006017A (es) * 2001-12-20 2005-06-08 Femmepharma Inc Suministro de farmacos por via vaginal.
MY138657A (en) 2001-12-21 2009-07-31 Tibotec Pharm Ltd broadspectrum heterocyclic substituted phenyl containing sulfonamide hiv protease inhibitors
US20030235619A1 (en) * 2001-12-21 2003-12-25 Christine Allen Polymer-lipid delivery vehicles
US20060177495A1 (en) * 2001-12-21 2006-08-10 Christine Allen Polymer-lipid delivery vehicles
AU2002364209A1 (en) * 2001-12-26 2003-07-24 Genelabs Technologies, Inc. Polyamide derivatives possessing antibacterial, antifungal or antitumor activity
US20030129242A1 (en) * 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
WO2003059319A1 (en) * 2002-01-14 2003-07-24 Dow Global Technologies Inc. Drug nanoparticles from template emulsions
IL162870A0 (en) 2002-02-01 2005-11-20 Pfizer Prod Inc Controlled release pharmaceutical dosage forms of a cholesteryl estertransfer protein inhibitor
AU2003210787B2 (en) 2002-02-01 2009-04-23 Medinol Ltd. Phosphorus-containing compounds & uses thereof
CA2475092C (en) 2002-02-04 2012-05-01 Christian F. Wertz Nanoparticulate compositions having lysozyme as a surface stabilizer
US7026465B2 (en) 2002-02-15 2006-04-11 Corixa Corporation Fusion proteins of Mycobacterium tuberculosis
MY142238A (en) 2002-03-12 2010-11-15 Tibotec Pharm Ltd Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
GB0206200D0 (en) * 2002-03-15 2002-05-01 Glaxo Group Ltd Pharmaceutical compositions
JP4611641B2 (ja) * 2002-03-20 2011-01-12 エラン ファーマ インターナショナル，リミティド Ｍａｐキナーゼ阻害剤のナノ粒子組成物
CA2479665C (en) * 2002-03-20 2011-08-30 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20030215502A1 (en) * 2002-03-20 2003-11-20 Elan Pharma International Limited Fast dissolving dosage forms having reduced friability
EP1800666A1 (de) * 2002-03-20 2007-06-27 Elan Pharma International Limited Nanopartikelzusammensetzungen von Angiogeneseinhibitoren
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
ES2300568T3 (es) 2002-03-20 2008-06-16 Mannkind Corporation Aparato de inhalacion.
US20040076586A1 (en) * 2002-03-28 2004-04-22 Reinhard Koening Compositions and methods for delivering pharmaceutically active agents using nanoparticulates
WO2003087763A2 (en) 2002-04-03 2003-10-23 Celltech R & D, Inc. Association of polymorphisms in the sost gene region with bone mineral density
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US9101540B2 (en) * 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US20100226989A1 (en) * 2002-04-12 2010-09-09 Elan Pharma International, Limited Nanoparticulate megestrol formulations
ES2380318T3 (es) 2002-04-12 2012-05-10 Alkermes Pharma Ireland Limited Formulaciones nanoparticulares de megestrol
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
DE10218109A1 (de) 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
US8501232B2 (en) * 2002-04-23 2013-08-06 Nanotherapeutics, Inc. Process of forming and modifying particles and compositions produced thereby
WO2004058686A1 (en) * 2002-04-30 2004-07-15 Elan Pharmaceuticals, Inc. Hydroxypropyl amides for the treatment of alzheimer’s disease
AU2003234452A1 (en) * 2002-05-06 2003-11-11 Elan Pharma International Ltd. Nanoparticulate nystatin formulations
WO2003097616A1 (en) 2002-05-17 2003-11-27 Tibotec Pharmaceuticals Ltd Broadspectrum substituted benzisoxazole sulfonamide hiv protease inhibitors
US8313760B2 (en) 2002-05-24 2012-11-20 Angiotech International Ag Compositions and methods for coating medical implants
PT1509256E (pt) * 2002-05-24 2009-10-15 Angiotech Int Ag Composições e métodos de revestimento de implantes médicos
US20070264348A1 (en) * 2002-05-24 2007-11-15 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
AU2003241477A1 (en) * 2002-06-10 2003-12-22 Elan Pharma International, Ltd. Nanoparticulate polycosanol formulations and novel polycosanol combinations
EP1531799A1 (de) * 2002-06-10 2005-05-25 Elan Pharma International Limited Pharmazeutische nanopartikel-formulierungen mit hmg-coa-reduktase-inhibitoren ("statine"), neue kombinationen davon sowie herstellung dieser pharmazeutischen zusammensetzungen
US20040258757A1 (en) * 2002-07-16 2004-12-23 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
GB0216700D0 (en) * 2002-07-18 2002-08-28 Astrazeneca Ab Process
US20030017208A1 (en) * 2002-07-19 2003-01-23 Francis Ignatious Electrospun pharmaceutical compositions
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
AU2002950426A0 (en) * 2002-07-29 2002-09-12 Patrick John Shanahan Anti microbial oro-dental system
US7838034B2 (en) 2002-07-30 2010-11-23 Grunenthal Gmbh Intravenous pharmaceutical form of administration
DE10234784A1 (de) * 2002-07-30 2004-02-19 Günenthal GmbH Intravenös applizierbare, pharmazeutische Darreichungsform
US20040023935A1 (en) * 2002-08-02 2004-02-05 Dey, L.P. Inhalation compositions, methods of use thereof, and process for preparation of same
US20040028746A1 (en) * 2002-08-06 2004-02-12 Sonke Svenson Crystalline drug particles prepared using a controlled precipitation (recrystallization) process
US20040028747A1 (en) * 2002-08-06 2004-02-12 Tucker Christopher J. Crystalline drug particles prepared using a controlled precipitation process
DE60329188D1 (de) 2002-08-12 2009-10-22 Bend Res Inc Arzneizubereitungen bestehend aus arzneimitteln in halb-geordneter form und polymeren
AU2003262574B2 (en) 2002-08-14 2009-07-09 Tibotec Pharmaceuticals Ltd. Broadspectrum substituted oxindole sulfonamide HIV protease inhibitors
US7445796B2 (en) * 2002-08-19 2008-11-04 L. Perrigo Company Pharmaceutically active particles of a monomodal particle size distribution and method
AU2003296897A1 (en) * 2002-08-20 2004-05-04 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
WO2004019873A2 (en) * 2002-08-29 2004-03-11 Scios Inc. Methods of promoting osteogenesis
AU2003276688A1 (en) * 2002-09-02 2004-03-19 Sun Pharmaceutical Industries Limited Pharmaceutical composition of metaxalone with enhanced oral bioavailability
ATE487470T1 (de) * 2002-09-11 2010-11-15 Elan Pharma Int Ltd Gel-stabilisierte wirkstoff-zusammensetzungen in nanoteilchengrösse
US20060189554A1 (en) * 2002-09-24 2006-08-24 Russell Mumper Nanoparticle-Based vaccine delivery system containing adjuvant
WO2004032980A1 (en) 2002-10-04 2004-04-22 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
US7473432B2 (en) * 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
EP1562555A2 (de) * 2002-10-24 2005-08-17 Enos Pharmaceuticals, Inc. L-arginin-formulierungen mit verzögerterfreisetzung und herstellungs- und verwendungsverfahren dafür
US20080145424A1 (en) * 2002-10-24 2008-06-19 Enos Phramaceuticals, Inc. Sustained release L-arginine formulations and methods of manufacture and use
AU2003291719A1 (en) * 2002-11-06 2004-06-03 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
ATE514418T1 (de) * 2002-11-12 2011-07-15 Elan Pharma Int Ltd Rasch zerfallende feste darreichungsformen mit nichtbröseliger konsistenz und pullulan
GB0227443D0 (en) * 2002-11-25 2002-12-31 Glaxo Group Ltd Pyrimidine derivatives
US7351738B2 (en) 2002-11-27 2008-04-01 Elan Pharmaceuticals, Inc. Substituted ureas and carbamates
AU2003302238A1 (en) 2002-12-03 2004-06-23 Axys Pharmaceuticals, Inc. 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
US20050095267A1 (en) * 2002-12-04 2005-05-05 Todd Campbell Nanoparticle-based controlled release polymer coatings for medical implants
US20040171659A1 (en) * 2002-12-06 2004-09-02 Satyanarayana Medicherla Methods for treating diabetes
US20040109826A1 (en) * 2002-12-06 2004-06-10 Dey, L.P. Stabilized albuterol compositions and method of preparation thereof
ATE411010T1 (de) * 2002-12-13 2008-10-15 Jagotec Ag Topische nanopartikel-spironolacton-formulierung
US20040173696A1 (en) * 2002-12-17 2004-09-09 Elan Pharma International Ltd. Milling microgram quantities of nanoparticulate candidate compounds
CA2886504C (en) 2002-12-20 2019-01-08 Celera Corporation Wdr12 polymorphisms associated with myocardial infarction, methods of detection and uses thereof
GB0230087D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0230088D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
JP2006515026A (ja) * 2003-01-02 2006-05-18 フェムファーマ ホールディング カンパニー， インコーポレイテッド 乳房の疾患および障害の処置のための薬学的調製物
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
RU2389732C2 (ru) 2003-01-06 2010-05-20 Корикса Корпорейшн Некоторые аминоалкилглюкозаминидфосфатные производные и их применение
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
CA2513064C (en) * 2003-01-31 2009-11-10 Elan Pharma International, Ltd. Nanoparticulate topiramate formulations
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
GB0302673D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302671D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
GB0302672D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
US20100297252A1 (en) 2003-03-03 2010-11-25 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
US8512727B2 (en) * 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
JP5137228B2 (ja) 2003-03-07 2013-02-06 メルク・シャープ・アンド・ドーム・コーポレーション 高コレステロール血症の処置のための置換アゼチジノン化合物、置換アゼチジノン処方物およびそれらの使用
DE602004018617D1 (de) 2003-03-07 2009-02-05 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
CN1756755A (zh) 2003-03-07 2006-04-05 先灵公司 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US20040184995A1 (en) * 2003-03-17 2004-09-23 Yamanouchi Pharmaceutical Co., Ltd. Novel dry powder inhalation for lung-delivery and manufacturing method thereof
JP2006521366A (ja) 2003-03-28 2006-09-21 シグモイド・バイオテクノロジーズ・リミテッド シームレスマイクロカプセルを含む固形経口剤形
AU2004230950C1 (en) * 2003-04-09 2011-08-04 Koppers Performance Chemicals Inc. Micronized wood preservative formulations
US8637089B2 (en) 2003-04-09 2014-01-28 Osmose, Inc. Micronized wood preservative formulations
US8747908B2 (en) 2003-04-09 2014-06-10 Osmose, Inc. Micronized wood preservative formulations
CL2004000848A1 (es) * 2003-04-21 2005-01-28 Elan Pharmaceuticals Inc Pharm Compuestos derivados de fenacil-2-hidroxi-3-diaminoalcanos, inhibidores de la enzima betasecretasa, utiles para preparar un medicamento para tratar alzheimer, sindrome de down, hemorragia cerebral hereditaria con amiloidosis de tipo holandes, y otras
CL2004000849A1 (es) 2003-04-21 2005-01-28 Elan Pharmaceuticals Inc Pharm Compuestos derivados de benzamidas-2-hidroxi-3-diaminoalcanos, utiles para el tratamiento o la prevencion de alzheimer, sindrome de down, hemorragia cerebral hereditaria, demencias degenerativas y otras.
EP1628641A2 (de) * 2003-05-19 2006-03-01 Baxter International Inc. Feste partikel, die ein antikonvulsivum oder ein immunsuppressivum enthalten und die mit einer oder mehreren oberflächen-modifizierenden substanzen beschichtet sind
KR20060006086A (ko) * 2003-05-20 2006-01-18 로레알 2가 산 코폴리머를 이용하여 크기를 안정화시킨 입자
FR2855051B1 (fr) * 2003-05-20 2006-08-25 Oreal Particules stabilisees en taille par copolymere diacide
CA2526454C (en) * 2003-05-22 2013-08-13 Applied Nanosystems B.V. Gel-assisted production of small particles
JP2007501683A (ja) * 2003-05-22 2007-02-01 エラン ファーマ インターナショナル リミテッド γ線照射によるナノ粒子活性物質分散体の滅菌法
US7109247B2 (en) * 2003-05-30 2006-09-19 3M Innovative Properties Company Stabilized particle dispersions containing nanoparticles
US7459146B2 (en) * 2003-05-30 2008-12-02 3M Innovative Properties Company Stabilized aerosol dispersions
DE10325989A1 (de) * 2003-06-07 2005-01-05 Glatt Gmbh Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung
NZ544618A (en) 2003-06-16 2009-02-28 Celltech R & D Inc Antibodies specific for sclerostin and methods for increasing bone mineralization
MXPA05013850A (es) 2003-06-17 2006-05-17 Phibro Tech Inc Conservador particulado para madera y metodo para producir el mismo.
US20060135523A1 (en) * 2003-06-18 2006-06-22 Astrazeneca Ab 2-substituted 5,6-diaryl-pyrazine derivatives as cb1 modulator
GB0314057D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
GB0314261D0 (en) * 2003-06-19 2003-07-23 Astrazeneca Ab Therapeutic agents
CA2540695A1 (en) * 2003-06-24 2004-12-29 Baxter International Inc. Specific delivery of drugs to the brain
US8986736B2 (en) * 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US8308682B2 (en) 2003-07-18 2012-11-13 Broncus Medical Inc. Devices for maintaining patency of surgically created channels in tissue
US20050042177A1 (en) * 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base
EP1652515A1 (de) * 2003-08-06 2006-05-03 Eisai Co., Ltd. Verfahren zur herstellung von arzneiultramikropartikeln und vorrichtung dafür
ES2318330T3 (es) * 2003-08-08 2009-05-01 Elan Pharma International Limited Nuevas composiciones de metaxalona.
US7419996B2 (en) * 2003-08-13 2008-09-02 The University Of Houston Parenteral and oral formulations of benzimidazoles
GB0319797D0 (en) * 2003-08-26 2003-09-24 Leuven K U Res & Dev Particle size reduction of poorly soluble drugs
BRPI0414082A (pt) * 2003-09-02 2006-10-24 Pfizer Prod Inc formas de dosagem de liberação sustentada de ziprasidona
WO2005020933A2 (en) * 2003-09-02 2005-03-10 University Of South Florida Nanoparticles for drug-delivery
NZ544980A (en) 2003-09-11 2009-02-28 Tibotec Pharm Ltd Entry inhibitors of the HIV virus
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
EP1663321B1 (de) 2003-09-22 2012-08-29 Baxter International Inc. Hochdrucksterilisation zur endsterilisation von pharmazeutischen präparaten und medizinprodukten
EP1675619A4 (de) * 2003-09-29 2010-10-06 Palmetto Pharmaceuticals Llc L-arginin-formulierungen mit verzögerter freisetzung und herstellungs- und verwendungsverfahren dafür
WO2005032551A1 (en) * 2003-09-30 2005-04-14 Scios Inc. TREATMENT OF CARDIOVASCULAR DISEASE WITH INHIBITORS OF p38 KINASE
PT1685126E (pt) * 2003-10-16 2007-04-30 Teva Pharma Preparação de candesartan cilexetil
US7338171B2 (en) * 2003-10-27 2008-03-04 Jen-Chuen Hsieh Method and apparatus for visual drive control
AU2003303744A1 (en) * 2003-10-31 2005-06-17 Elan Pharma International Ltd. Novel nimesulide compositions
WO2005046797A2 (en) * 2003-11-05 2005-05-26 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
ES2366646T3 (es) * 2003-11-05 2011-10-24 Elan Pharma International Limited Composiciones en forma de nanopartículas que tienen un péptido como estabilizante superficial.
CA2536188A1 (en) * 2003-11-20 2005-06-09 Angiotech International Ag Electrical devices and anti-scarring agents
CZ300438B6 (cs) * 2003-11-25 2009-05-20 Pliva Hrvatska D.O.O. Zpusob prípravy orální pevné lékové formy s okamžitým uvolnováním úcinné látky obsahující jako úcinnou látku polymorfní formu finasteridu
WO2005053851A1 (en) * 2003-11-26 2005-06-16 E.I. Dupont De Nemours And Company High pressure media milling system and process of milling particles
CA3050151C (en) 2003-11-26 2023-03-07 Celera Corporation Single nucleotide polymorphisms associated with cardiovascular disorders and statin response, methods of detection and uses thereof
CN1878602A (zh) * 2003-11-28 2006-12-13 三菱化学株式会社 有机化合物微粒的制造方法
JP5107579B2 (ja) * 2003-12-02 2012-12-26 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション 新規の種類のヒストン脱アセチル化酵素阻害剤としてのＺｎ２＋キレートモチーフ係留短鎖脂肪酸
KR100603974B1 (ko) 2003-12-05 2006-07-25 김갑식 고체상 지질을 용매로 이용한 나노수준의 또는 비결정질입자의 제조 방법
JP2007517892A (ja) * 2004-01-12 2007-07-05 マンカインド コーポレイション ２型糖尿病における血清プロインスリンレベルを低下させる方法
JP2007522129A (ja) * 2004-01-21 2007-08-09 エラン ファーマシューティカルズ，インコーポレイテッド アスパラギン酸プロテアーゼ阻害薬を用いるアミロイドーシスの処置方法
WO2005072710A2 (en) * 2004-01-28 2005-08-11 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
CA2554246A1 (en) * 2004-01-29 2005-08-11 Baxter International Inc. Nanosuspensions of anti-retroviral agents for increased central nervous system delivery
US20050169978A1 (en) * 2004-01-29 2005-08-04 Shu-Wen Fu Wet-micro grinding
CA2555294A1 (en) * 2004-02-11 2005-08-25 Marina Yu Etinger Candesartan cilexetil polymorphs
WO2005087714A2 (en) * 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
CA2558249A1 (en) * 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors
JP2007528400A (ja) * 2004-03-09 2007-10-11 エラン ファーマシューティカルズ，インコーポレイテッド 置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
US20060014737A1 (en) * 2004-03-09 2006-01-19 Varghese John Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors
EP1735293A2 (de) * 2004-03-09 2006-12-27 Elan Pharmaceuticals, Inc. Substituierte hydroxyethylamine als aspartylproteaseinhibitoren
WO2005088655A1 (en) * 2004-03-12 2005-09-22 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin A magnetoresistive medium
US20080090753A1 (en) * 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20050202051A1 (en) * 2004-03-15 2005-09-15 Chinea Vanessa I. Pharmaceutical vehicle
US20050203482A1 (en) * 2004-03-15 2005-09-15 Chinea Vanessa I. Pharmaceutical dispensing apparatus and method
DE602005005033T2 (de) * 2004-03-30 2009-03-19 Smithkline Beecham Corp. Sprühgetrocknete pharmazeutische zusammensetzungen
PL1731138T3 (pl) * 2004-03-31 2016-10-31 Drobnoziarnista dyspersja słabo rozpuszczalnego leku i sposób jej wytwarzania
AR048650A1 (es) 2004-05-04 2006-05-10 Tibotec Pharm Ltd Derivados de (1,10b-dihidro-2-(aminocarbonil-fenil)-5h-pirazolo[1,5 c][1,3]benzoxazin-5-il)fenil metanona como inhibidores de la replicacion viral del vih
MXPA06012702A (es) * 2004-05-05 2007-04-02 Teva Pharma Preparacion de candesartan cilexetil de alta pureza.
EP1745154B1 (de) 2004-05-07 2012-08-01 Celera Corporation Genetische polymorphismen assoziiert mit leberfibrose, verfahren zur detektion und verwendung davon
US7378441B2 (en) 2004-05-07 2008-05-27 Sequoia Pharmaceuticals, Inc. Resistance-repellent retroviral protease inhibitors
US20050252408A1 (en) 2004-05-17 2005-11-17 Richardson H W Particulate wood preservative and method for producing same
TW200613307A (en) 2004-05-17 2006-05-01 Tibotec Pharm Ltd 4-substituted-1,5-dihydro-pyrido[3,2-b]indol-2-ones
AR049340A1 (es) 2004-05-17 2006-07-19 Tibotec Pharm Ltd 1- heterociclil - l, 5- dihidro- pirido (3,2-b) indol - 2- onas
ES2351702T3 (es) 2004-05-17 2011-02-09 Tibotec Pharmaceuticals 1-fenil-1,5-dihidro-pirido[3,2-b]indol-2-onas 6,7,8,9-sustituidas útiles como agentes farmacéuticos antiinfecciosos.
US7316738B2 (en) * 2004-10-08 2008-01-08 Phibro-Tech, Inc. Milled submicron chlorothalonil with narrow particle size distribution, and uses thereof
EP2497831B1 (de) 2004-05-25 2014-07-16 Oregon Health and Science University TB-Impfung unter Verwendung von Impfvektoren auf HCMV-Basis
EP1750677B1 (de) * 2004-05-28 2017-02-01 Imaginot Pty Ltd. Abgabesystem für eine orale therapeutische verbindung
US8216610B2 (en) * 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
WO2005117997A1 (en) * 2004-06-01 2005-12-15 The Ohio State University Ligands having metal binding ability and targeting properties
US8012457B2 (en) 2004-06-04 2011-09-06 Acusphere, Inc. Ultrasound contrast agent dosage formulation
CN101310011A (zh) * 2004-06-15 2008-11-19 巴克斯特国际公司 固相微颗粒治疗剂的离体应用
WO2006002088A2 (en) * 2004-06-21 2006-01-05 The Ohio State University Research Foundation Amino-quinazoline derivatives as antitumor agents
US7385085B2 (en) * 2004-07-09 2008-06-10 Elan Pharmaceuticals, Inc. Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
EP1773758A1 (de) * 2004-07-09 2007-04-18 Elan Pharmaceuticals, Inc. Oximderivathydroxyethylaminaspartylproteaseinhibitoren
AU2005269800B8 (en) 2004-07-19 2011-12-01 Celator Pharmaceuticals, Inc. Particulate constructs for release of active agents
US8409167B2 (en) 2004-07-19 2013-04-02 Broncus Medical Inc Devices for delivering substances through an extra-anatomic opening created in an airway
WO2006023639A1 (en) * 2004-08-18 2006-03-02 Concordia Pharmaceuticals, Inc. Methods and compositions for oral delivery of fts
WO2006023286A2 (en) * 2004-08-19 2006-03-02 Alza Corporation Controlled release nanoparticle active agent formulation dosage forms and methods
MX2007001903A (es) 2004-08-20 2007-08-02 Mannkind Corp Catalisis de sintesis de dicetopiperazina.
KR101306384B1 (ko) 2004-08-23 2013-09-09 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는디케토디옥산염
GB0418791D0 (en) * 2004-08-23 2004-09-22 Glaxo Group Ltd Novel process
WO2006026502A1 (en) * 2004-08-27 2006-03-09 The Dow Chemical Company Enhanced delivery of drug compositions to treat life threatening infections
CA2577392A1 (en) * 2004-08-27 2006-03-09 Elan Pharmaceuticals, Inc. Methods of treatment of amyloidosis using ethanol cyclicamine derivatives aspartyl protease inhibitors
WO2006028074A1 (ja) * 2004-09-07 2006-03-16 Mitsubishi Chemical Corporation 微粒子化された物質の製造方法および微粒子化された物質
WO2006034147A2 (en) * 2004-09-16 2006-03-30 Abraxis Bioscience, Inc. Compositions and methods for the preparation and administration of poorly water soluble drugs
US20080020018A1 (en) * 2004-09-27 2008-01-24 Joey Moodley Combination Products
US7426948B2 (en) * 2004-10-08 2008-09-23 Phibrowood, Llc Milled submicron organic biocides with narrow particle size distribution, and uses thereof
SI1799776T1 (sl) 2004-10-14 2013-05-31 Osmose, Inc. Mikronizirane formulacije za konzerviranje lesa v organskih nosilcih
KR100651728B1 (ko) * 2004-11-10 2006-12-06 한국전자통신연구원 정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
US20080095722A1 (en) * 2004-11-12 2008-04-24 Idea Ag Extended Surface Aggregates in the Treatment of Skin Conditions
US20090155331A1 (en) * 2005-11-16 2009-06-18 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
EA200701065A1 (ru) * 2004-11-16 2007-12-28 Элан Фарма Интернэшнл Лтд. Инъецируемые составы, содержащие нанодисперсный оланзапин
US7414031B2 (en) * 2004-11-22 2008-08-19 Genelabs Technologies, Inc. 5-nitro-nucleoside compounds for treating viral infections
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
JPWO2006062238A1 (ja) * 2004-12-07 2008-06-12 味の素株式会社 アミノ酸の微粉末及びその懸濁液
WO2006062875A1 (en) * 2004-12-08 2006-06-15 Merck & Co., Inc. Ophthalmic nanoparticulate formulation of a cyclooxygenase-2 selective inhibitor
JP2008524239A (ja) * 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミティド ナノ粒子のタクロリムス製剤
US20110177306A1 (en) * 2004-12-17 2011-07-21 Mitsubishi Chemical Corporation Novel Core-Shell Structure
US20060159767A1 (en) * 2004-12-22 2006-07-20 Elan Pharma International Limited Nanoparticulate bicalutamide formulations
BRPI0518101A (pt) * 2004-12-31 2008-10-28 Iceutica Pty Ltd métodos de produção e sìntese de composições nanoparticuladas, composições obtidas e seu uso
AU2005321751B2 (en) * 2004-12-31 2012-04-05 Iceutica Pty Ltd Nanoparticle composition and methods for synthesis thereof
AU2012201630B8 (en) * 2004-12-31 2014-03-06 Iceutica Pty Ltd NanoParticle Composition(s) and Method for Synthesis Thereof
EP1835890A2 (de) * 2005-01-06 2007-09-26 Elan Pharma International Limited Candesartan-nanopartikelformulierungen
EP1834624A4 (de) * 2005-01-07 2011-05-04 Eisai R&D Man Co Ltd Medizinische zusammensetzung und herstellungsverfahren dafür
JP5288791B2 (ja) * 2005-01-28 2013-09-11 武田薬品工業株式会社 難水溶性物質含有微細化組成物
ES2265262B1 (es) * 2005-01-31 2008-03-01 Activery Biotech, S.L.(Titular Al 50%) Procedimiento para la obtencion de sistemas micro- y nanodispersos.
EP1885746B1 (de) 2005-02-08 2012-01-11 Research Development Foundation Zusammensetzungen in zusammenhang mit löslichen, g-proteingekoppelten rezeptoren (sgpcrs)
AU2006214443C1 (en) * 2005-02-15 2011-11-24 Alkermes Pharma Ireland Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
EP1853617A1 (de) * 2005-02-28 2007-11-14 Genelabs Technologies, Inc. Tricyclische nukleosid-prodrugs zur behandlung viraler infektionen
AU2005100176A4 (en) * 2005-03-01 2005-04-07 Gym Tv Pty Ltd Garbage bin clip
US20080254114A1 (en) * 2005-03-03 2008-10-16 Elan Corporation Plc Controlled Release Compositions Comprising Heterocyclic Amide Derivative Nanoparticles
WO2006099121A2 (en) * 2005-03-10 2006-09-21 Elan Pharma International Limited Formulations of a nanoparticulate finasteride, dutasteride and tamsulosin hydrochloride, and mixtures thereof
WO2006099365A2 (en) 2005-03-11 2006-09-21 Applera Corporation Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof
CA2601179A1 (en) * 2005-03-16 2006-09-21 Elan Pharma International Limited Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations
JP2008533173A (ja) * 2005-03-17 2008-08-21 エラン ファーマ インターナショナル リミテッド ナノ粒子ビスホスホネート組成物
KR20070121786A (ko) * 2005-03-23 2007-12-27 엘란 파마 인터내셔널 리미티드 나노입자형 코르티코스테로이드 및 항히스타민 제제
US20070224282A1 (en) * 2005-03-28 2007-09-27 Toyama Chemical Co., Ltd. Fine Dispersion of Sparingly Soluble Drug and Process for Producing the Same
WO2006104890A2 (en) 2005-03-31 2006-10-05 Glaxosmithkline Biologicals Sa Vaccines against chlamydial infection
TW200710091A (en) 2005-04-11 2007-03-16 Tibotec Pharm Ltd (1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors
BRPI0607537A2 (pt) * 2005-04-12 2009-09-15 Elan Pharma Int Ltd formulações de derivado de quinazolina nanoparticulado
CN101171000A (zh) * 2005-04-12 2008-04-30 依兰药物国际有限公司 包含环孢菌素的毫微粒和控制释放组合物
US20060246141A1 (en) * 2005-04-12 2006-11-02 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
US9248101B2 (en) * 2005-04-13 2016-02-02 Abbvie Deutschland Gmbh & Co Kg Method for the gentle production of ultrafine particle suspensions and ultrafine particles and the use thereof
WO2006113310A2 (en) * 2005-04-13 2006-10-26 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising prostaglandin derivatives
CN101166514A (zh) * 2005-04-13 2008-04-23 辉瑞产品公司 用于提供持续释放的纳米粒组合物的可注射储库制剂及方法
US20080305161A1 (en) * 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
ITMI20050739A1 (it) * 2005-04-22 2006-10-23 Effebi Spa Piastrina di connsessione valvola-attuatore
WO2006116557A1 (en) * 2005-04-25 2006-11-02 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
JP5164830B2 (ja) 2005-04-29 2013-03-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 結核菌感染の予防または治療のための新規方法
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
ES2429941T3 (es) * 2005-05-10 2013-11-18 Teva Pharmaceutical Industries, Ltd. Candesartán cilexetilo micronizado estable y métodos para preparar el mismo
JP2008540550A (ja) * 2005-05-10 2008-11-20 エラン・ファルマ・インターナショナル・リミテッド ビタミンｋ２を含むナノ粒子および制御放出組成物
MX2007014163A (es) * 2005-05-10 2008-01-24 Elan Pharma Int Ltd Formulaciones de nanoparticulas de clopidogrel.
WO2006132752A1 (en) * 2005-05-10 2006-12-14 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising vitamin k2
EP1915139A1 (de) * 2005-05-16 2008-04-30 Elan Pharma International Limited Nanoteilchenförmige und kontrolliert freigesetzte zusammensetzungen mit einem cephalosporin
JP2008545808A (ja) * 2005-05-23 2008-12-18 エラン・ファルマ・インターナショナル・リミテッド 血小板凝集阻害薬を含むナノ粒子状および制御放出組成物
BRPI0613540A2 (pt) 2005-06-03 2011-01-18 Elan Pharma Int Ltd formulações de imatinib mesilato nanoparticuladas
EP1901728A2 (de) * 2005-06-03 2008-03-26 Elan Pharma International Limited Acetaminophen-nanopartikelformulierungen
WO2006133045A1 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate benidipine compositions
JP5284779B2 (ja) * 2005-06-07 2013-09-11 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド コンジュゲート化された向精神薬の新規な塩およびその調製方法
JP2009517485A (ja) * 2005-06-08 2009-04-30 エラン・ファルマ・インターナショナル・リミテッド セフジトレンを含むナノ粒子状および制御放出組成物
WO2006135689A2 (en) * 2005-06-09 2006-12-21 Elan Pharma International, Limited Nanoparticulate ebastine formulations
CA2611741A1 (en) * 2005-06-13 2006-12-28 Elan Pharma International, Limited Nanoparticulate clopidogrel and aspirin combination formulations
CA2612384A1 (en) * 2005-06-15 2006-12-28 Elan Pharma International, Limited Nanoparticulate azelnidipine formulations
CA2613474A1 (en) * 2005-06-20 2007-03-08 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds
AU2006262144A1 (en) * 2005-06-22 2007-01-04 Elan Pharma International, Limited Nanoparticulate megestrol formulations
AU2006261132A1 (en) * 2005-06-24 2006-12-28 Genelabs Technologies, Inc. Heteroaryl derivatives for treating viruses
WO2007000842A1 (ja) * 2005-06-29 2007-01-04 Mitsubishi Chemical Corporation 粒状物分散組成物及びその製造方法、並びに、粒状物及び医薬品
CN101212964A (zh) * 2005-06-29 2008-07-02 帝斯曼知识产权资产管理有限公司 异黄酮纳米颗粒及其用途
US8074906B2 (en) * 2005-07-07 2011-12-13 Nanotherapeutics, Inc. Process for milling and preparing powders and compositions produced thereby
US20070298109A1 (en) * 2005-07-07 2007-12-27 The Trustees Of The University Of Pennsylvania Nano-scale devices
WO2007008537A2 (en) * 2005-07-07 2007-01-18 Elan Pharma International, Limited Nanoparticulate clarithromycin formulations
EP1906919A4 (de) * 2005-07-15 2012-12-26 Map Pharmaceuticals Inc Mehrere pharmazeutische wirkstoffe in kombination in diskreten inhalierbaren teilchen und formulierungen davon
WO2007016597A2 (en) * 2005-07-29 2007-02-08 The Regents Of The University Of California Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy
BRPI0614757A2 (pt) * 2005-08-10 2011-04-12 Novartis Ag composição farmacêutica, micropartìcula e seu uso
CA2617873A1 (en) * 2005-08-10 2007-02-15 Novartis Ag Formulations for 7-(t-butoxy)iminomethyl camptothecin
WO2007021228A1 (en) * 2005-08-12 2007-02-22 Astrazeneca Ab Process
GB0516549D0 (en) * 2005-08-12 2005-09-21 Sulaiman Brian Milling system
US8034765B2 (en) * 2005-08-31 2011-10-11 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
KR101420445B1 (ko) 2005-08-31 2014-07-16 아브락시스 바이오사이언스, 엘엘씨 수 난용성 제약학적 약제 및 항균제를 포함하는 조성물
US20080213383A1 (en) * 2005-09-06 2008-09-04 Astellas Pharma Inc. Fine particles of poorly water-soluble drug having enteric material adsorbed on particle surface
JP2009507925A (ja) * 2005-09-13 2009-02-26 エラン ファーマ インターナショナル リミテッド ナノ粒子タダラフィル製剤
JP5465878B2 (ja) 2005-09-14 2014-04-09 マンカインド コーポレイション 活性薬剤に対する結晶性微粒子表面の親和性を増大させることに基づく薬物処方の方法
JP2009508859A (ja) * 2005-09-15 2009-03-05 エラン ファーマ インターナショナル リミテッド ナノ粒子アリピプラゾール製剤
US7799530B2 (en) 2005-09-23 2010-09-21 Celera Corporation Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
US8084420B2 (en) * 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US20070086952A1 (en) * 2005-09-29 2007-04-19 Biodel, Inc. Rapid Acting and Prolonged Acting Inhalable Insulin Preparations
US20070077309A1 (en) * 2005-09-30 2007-04-05 Wong Patrick S Banded controlled release nanoparticle active agent formulation dosage forms and methods
NZ594628A (en) 2005-10-07 2013-04-26 Exelixis Inc PYRIDOPYRIMIDINONE INHIBITORS OF PI3Ka
CA2623768C (en) 2005-10-07 2016-04-12 Exelixis, Inc. N-(3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
WO2007047305A1 (en) * 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
CA2624904A1 (en) * 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors
US7695911B2 (en) 2005-10-26 2010-04-13 Celera Corporation Genetic polymorphisms associated with Alzheimer's Disease, methods of detection and uses thereof
DE102005053862A1 (de) * 2005-11-04 2007-05-10 Pharmasol Gmbh Verfahren und Vorrichtung zur Herstellung hochfeiner Partikel sowie zur Beschichtung solcher Partikel
AU2006318212C1 (en) 2005-11-23 2012-08-30 The Board Of Regents Of The University Of Texas System Oncogenic ras-specific cytotoxic compound and methods of use thereof
EA017290B1 (ru) * 2005-11-28 2012-11-30 Домейн Раша Инвестментс Лимитед Композиции на основе ганаксолона
EP1954298A4 (de) * 2005-11-28 2012-10-31 Imaginot Pty Ltd Abgabesystem für eine orale therapeutische verbindung
CA2631757A1 (en) * 2005-12-02 2007-06-07 Elan Pharma International Limited Novel mometasone compositions and methods of making and using the same
EP1976829A2 (de) * 2005-12-12 2008-10-08 Genelabs Technologies, Inc. N-(6-gliedriger aromatischer ring)-amidoverbindungen mit antiviraler wirkung
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
US20070178049A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070160542A1 (en) * 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
CN103265495B (zh) 2005-12-29 2016-11-16 莱西肯医药有限公司 多环氨基酸衍生物及其使用方法
US20090081157A1 (en) 2006-01-09 2009-03-26 Richard Syd Kornbluth Immunostimulatory Combinations for Vaccine Adjuvants
JP2009526860A (ja) * 2006-02-15 2009-07-23 ティカ レーケメデル アーベー 安定したコルチコステロイド混合物
CN104383546B (zh) 2006-02-22 2021-03-02 曼金德公司 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法
JP2009527504A (ja) * 2006-02-23 2009-07-30 イオメディックス スリープ インターナショナル エスアールエル 良質な睡眠の誘導および維持のための組成物および方法
US7649098B2 (en) 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
US20090099175A1 (en) * 2006-03-01 2009-04-16 Arrington Mark P Phosphodiesterase 10 inhibitors
AU2007224006A1 (en) * 2006-03-07 2007-09-13 Novavax, Inc. Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same
US11311477B2 (en) 2006-03-07 2022-04-26 Sgn Nanopharma Inc. Ophthalmic preparations
US10137083B2 (en) 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
EP1993513A4 (de) * 2006-03-14 2012-06-27 Merck Sharp & Dohme Verfahren und vorrichtung für die zubereitung von kristallinen organischen mikropartikelzusammensetzungen mittels mikromahlen und kristallisierung von mikrosamen und ihre verwendung
RU2008143342A (ru) 2006-04-03 2010-05-10 Тиботек Фармасьютикалз Лтд. (Ie) 3, 4-дигидроимидазо(4, 5-b)пиридин-5-оны, ингибирующие вич(hiv)
WO2007121256A2 (en) * 2006-04-12 2007-10-25 Biodel, Inc. Rapid acting and long acting insulin combination formulations
WO2008054508A2 (en) * 2006-04-13 2008-05-08 Alza Corporation Stable nanosized amorphous drug
LT2010528T (lt) 2006-04-19 2017-12-27 Novartis Ag 6-o-pakeistieji benzoksazolo junginiai bei csf-1r signalo perdavimo slopinimo būdai
JP2007306950A (ja) 2006-05-15 2007-11-29 Osaka Univ 薬効成分ナノ粒子分散液の製造方法
US20070275052A1 (en) * 2006-05-24 2007-11-29 Glenmark Pharmaceuticals Limited Pharmaceutical compositions containing sterol inhibitors
MX2008015275A (es) 2006-05-30 2009-02-06 Elan Pharma Int Ltd Formulaciones de posaconazol en nanoparticulas.
US20130197527A1 (en) * 2006-06-12 2013-08-01 Smith & Nephew, Inc. Systems, methods and devices for tibial resection
CA2660647C (en) 2006-06-14 2015-07-28 Intervet International B.V. A suspension comprising benzimidazole carbamate and a polysorbate
CL2007001847A1 (es) 2006-06-23 2008-02-08 Tibotec Pharm Ltd Composicion farmaceutica intramuscular o subcutanea que comprende tmc278 (rilpivirina); proceso para preparar la composicion; y uso para el tratamiento o prevencion de infeccion por vih.
WO2008002485A2 (en) * 2006-06-23 2008-01-03 Alza Corporation Increased amorphous stability of poorly water soluble drugs by nanosizing
AU2007265452A1 (en) * 2006-06-26 2008-01-03 Mutual Pharmaceutical Company, Inc. Active agent formulations, methods of making, and methods of use
EP2041088B1 (de) 2006-06-28 2014-01-08 Amgen Inc. Inhibitoren des glycintransporters 1
JP5508003B2 (ja) 2006-06-30 2014-05-28 アイスイティカ ピーティーワイ リミテッド ナノ粒子状の形態における生物学的に活性な化合物の調製のための方法
US8808751B2 (en) * 2006-06-30 2014-08-19 Iceutica Pty Ltd. Methods for the preparation of biologically active compounds in nanoparticulate form
WO2008008733A2 (en) * 2006-07-10 2008-01-17 Elan Pharma International Ltd. Nanoparticulate sorafenib formulations
AU2007274583B2 (en) * 2006-07-17 2012-11-01 Bar-Ilan University Conjugates comprising a psychotropic drug or a GABA agonist and an organic acid and their use in treating pain and other CNS disorders
TW200817413A (en) * 2006-07-20 2008-04-16 Genelabs Tech Inc Polycyclic viral inhibitors
WO2008013416A1 (en) * 2006-07-27 2008-01-31 Amorepacific Corporation Process for preparing powder comprising nanoparticles of sparingly soluble drug
WO2008022281A1 (en) * 2006-08-16 2008-02-21 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Small molecule inhibitors of kynurenine-3-monooxygenase
WO2008022286A2 (en) * 2006-08-16 2008-02-21 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Small molecule inhibitors of kynurenine-3-monooxygenase
EP2057151A4 (de) * 2006-08-28 2010-07-21 Hetero Drugs Ltd Verfahren zur reinigung von aprepitant
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
WO2008030557A2 (en) * 2006-09-08 2008-03-13 Johns Hopkins University Compositions and methods for enhancing transport through mucus
WO2008085556A2 (en) 2006-09-12 2008-07-17 University Of South Florida Surfactant-free nanoparticles for drug delivery
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
WO2008032327A2 (en) * 2006-09-14 2008-03-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Organic nanoparticles obtained from microemulsions by solvent evaporation
AR063704A1 (es) * 2006-09-14 2009-02-11 Makhteshim Chem Works Ltd Nanoparticulas de pesticida obtenida obtenidas a partir de microemulsiones y nanoemulsiones
CL2007002689A1 (es) 2006-09-18 2008-04-18 Vitae Pharmaceuticals Inc Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
AU2007298674A1 (en) * 2006-09-22 2008-03-27 Labopharm (Barbados) Limited Compositions and methods for pH targeted drug delivery
CN1946120B (zh) * 2006-10-20 2010-05-12 华为技术有限公司 实现话单关联的方法及系统
CA2915679C (en) 2006-10-20 2017-12-12 Celera Corporation Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof
US8946200B2 (en) * 2006-11-02 2015-02-03 Southwest Research Institute Pharmaceutically active nanosuspensions
US20100015665A1 (en) * 2006-11-10 2010-01-21 Ucb Pharma S.A. Antibodies and diagnostics
EP2097450A2 (de) * 2006-11-10 2009-09-09 Amgen Inc. Diagnostika und therapeutika auf antikörperbasis
CA2669392C (en) * 2006-11-17 2016-05-10 Abbott Gmbh & Co. Kg Nanocrystals for use in topical cosmetic formulations and method of production thereof
KR20080047957A (ko) * 2006-11-27 2008-05-30 주식회사 엠디바이오알파 고혈압의 치료 및 예방을 위한 약제 조성물
JP2010510988A (ja) * 2006-11-28 2010-04-08 マリナス ファーマシューティカルズ ナノ粒子製剤とその製造方法およびその利用
US20090028935A1 (en) * 2006-12-01 2009-01-29 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
US20080292695A1 (en) * 2006-12-01 2008-11-27 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
EP1938800A1 (de) 2006-12-06 2008-07-02 Ranbaxy Laboratories Limited Sirolimus-Nanodispersion
UA99270C2 (en) 2006-12-12 2012-08-10 Лексикон Фармасьютикалз, Инк. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
CA2674078C (en) * 2006-12-26 2012-03-20 Femmepharma Holding Company, Inc. Topical administration of danazol
DE102007001473A1 (de) 2007-01-08 2008-07-10 Andreas Lemke Verfahren zur Herstellung und Anwendung von Mikro- und/oder Nanosuspensionen durch aufbauende Mikronisierung in Gegenwart von Trockeneis und hohem Druck
EP2109443A4 (de) * 2007-02-09 2012-08-22 Astrazeneca Ab Verfahren zur herstellung einer stabilen dispersion aus festen amorphen submikron-partikeln in einem wässrigen medium
TW200848039A (en) * 2007-02-09 2008-12-16 Astrazeneca Ab Pharmaceutical compositions
KR20090129998A (ko) 2007-02-11 2009-12-17 맵 파마슈티컬스, 인코포레이티드 부작용 프로파일을 최소화하면서 편두통의 빠른 완화를 가능하게 하는 ｄｈｅ의 치료적 투여 방법
EP2134327A1 (de) * 2007-03-13 2009-12-23 Sandoz AG Pharmazeutische zusammensetzungen schlecht löslicher arzneimittel
AR065720A1 (es) 2007-03-14 2009-06-24 Tibotec Pharm Ltd Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
EA018441B1 (ru) 2007-03-14 2013-08-30 ЭКСЕЛИКСИС ПАТЕНТ КОМПАНИ ЭлЭлСи Ингибиторы пути хеджхога
CA2683415C (en) 2007-04-04 2020-12-08 Sigmoid Pharma Limited An oral pharmaceutical composition
WO2008124522A2 (en) * 2007-04-04 2008-10-16 Biodel, Inc. Amylin formulations
TWI405590B (zh) * 2007-04-06 2013-08-21 Activus Pharma Co Ltd 微粉碎化有機化合物粒子之製法
EP3492596A1 (de) 2007-04-09 2019-06-05 University of Florida Research Foundation, Inc. Raav-vektorzusammensetzungen mit tyrosinmodifizierten kapsidproteinen und verfahren zu deren verwendung
EP2586428B1 (de) 2007-04-26 2023-11-08 Sublimity Therapeutics Limited Herstellung mehrerer Minikapseln
EP2063875A2 (de) * 2007-05-01 2009-06-03 Sigmoid Pharma Limited Pharmazeutische kombinationszusammensetzungen
WO2008135855A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
WO2008135828A2 (en) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US8530463B2 (en) * 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
US20080279784A1 (en) * 2007-05-07 2008-11-13 Questcor Pharmaceuticals, Inc. Nasal administration of benzodiazepines
CA2685967A1 (en) 2007-05-21 2008-11-21 Novartis Ag Csf-1r inhibitors, compositions, and methods of use
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
JP5596540B2 (ja) * 2007-05-31 2014-09-24 ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド 安定な機能性ナノ粒子を形成する方法
US8974827B2 (en) 2007-06-04 2015-03-10 Bend Research, Inc. Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
US9545384B2 (en) 2007-06-04 2017-01-17 Bend Research, Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate
WO2009006479A2 (en) 2007-07-02 2009-01-08 Etubics Corporation Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
JP4419157B2 (ja) 2007-07-06 2010-02-24 エム・テクニック株式会社 生体摂取物微粒子の製造方法
DK2175857T3 (da) 2007-07-12 2013-12-02 Janssen R & D Ireland Krystallinsk form af (e) 4-[[4-[[4-(2-cyanoethenyl)-2.6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitril
WO2009010837A2 (en) 2007-07-13 2009-01-22 Pfizer Products Inc. Nanoparticles comprising a non-ionizable polymer and an anionic cellulosic polymer
JP2010535773A (ja) * 2007-08-10 2010-11-25 グラクソスミスクライン エルエルシー ウイルス感染を治療するための窒素含有二環式化学物質
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
EP2772267B1 (de) 2007-08-27 2016-04-27 Longhorn Vaccines and Diagnostics, LLC Immunogene Zusammensetzungen und Verfahren
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
WO2009029729A1 (en) * 2007-08-31 2009-03-05 Genelabs Technologies, Inc. Amino tricyclic-nucleoside compounds, compositions, and methods of use
CA2699172C (en) 2007-09-03 2016-05-17 Nanotherapeutics, Inc Compositions and methods for delivery of poorly soluble drugs
US20090068266A1 (en) * 2007-09-11 2009-03-12 Raheja Praveen Sirolimus having specific particle size and pharmaceutical compositions thereof
US20090130210A1 (en) * 2007-09-11 2009-05-21 Raheja Praveen Pharmaceutical compositions of sirolimus
US8232413B2 (en) * 2007-09-12 2012-07-31 Merck Sharp & Dohme Corp. Process for the production of a crystalline glucagon receptor antagonist compound
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
AU2008303129B2 (en) * 2007-09-25 2013-08-01 Formulex Pharma Innovations Ltd. Compositions comprising lipophilic active compounds and method for their preparation
CA2861667C (en) 2007-10-01 2017-06-13 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system and methods of use
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
CN101820873A (zh) * 2007-10-11 2010-09-01 麦仁斯有限公司 包含萘醌基化合物的微粉化粒子的药物组合物
US8486043B2 (en) * 2007-10-12 2013-07-16 Map Pharmaceuticals, Inc. Inhalation drug delivery
US9206233B2 (en) * 2007-10-19 2015-12-08 University of Pittsburgh—of the Commonwealth System of Higher Education Templates for controlling synthesis of nanoparticles into discrete assemblies
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
US8642062B2 (en) 2007-10-31 2014-02-04 Abbott Cardiovascular Systems Inc. Implantable device having a slow dissolving polymer
US8039212B2 (en) 2007-11-05 2011-10-18 Celera Corporation Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof
JP2011503232A (ja) 2007-11-20 2011-01-27 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 免疫応答の調節
US8598165B2 (en) * 2007-11-26 2013-12-03 University Of Kansas Morpholines as selective inhibitors of cytochrome P450 2A13
AU2008329677B2 (en) 2007-11-28 2015-02-19 Sequoia Pharmaceuticals, Inc. Compositions and methods for inhibiting cytochrome P450 2D6
WO2009073215A1 (en) 2007-12-06 2009-06-11 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
US9233078B2 (en) 2007-12-06 2016-01-12 Bend Research, Inc. Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer
KR100961880B1 (ko) * 2007-12-12 2010-06-09 중앙대학교 산학협력단 밀링에 의한 기능성 약물나노입자의 제조방법 및 상기제조방법에 의해 입자 표면이 개질된 약물나노입자 제제
US20090238867A1 (en) * 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
AU2008338464A1 (en) * 2007-12-14 2009-06-25 Amgen Inc. Method for treating bone fracture with anti-sclerostin antibodies
CN101952282A (zh) 2007-12-20 2011-01-19 诺瓦提斯公司 用作pi 3激酶抑制剂的噻唑衍生物
JP2011507906A (ja) * 2007-12-21 2011-03-10 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー フラビウイルス感染の治療に用いるための縮合５環式誘導体
US9242295B2 (en) 2007-12-21 2016-01-26 The Univeristy Of Texas At Arlington Bulk nanocomposite magnets and methods of making bulk nanocomposite magnets
US20100054981A1 (en) 2007-12-21 2010-03-04 Board Of Regents, The University Of Texas System Magnetic nanoparticles, bulk nanocomposite magnets, and production thereof
KR101405823B1 (ko) * 2007-12-24 2014-06-12 주식회사 케이티앤지생명과학 녹내장의 치료 및 예방을 위한 약제 조성물
KR20090071829A (ko) * 2007-12-28 2009-07-02 주식회사 머젠스 신장질환의 치료 및 예방을 위한 약제 조성물
AU2009204309B2 (en) * 2008-01-04 2012-11-22 Biodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
IL188647A0 (en) 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
US20090202649A1 (en) * 2008-02-06 2009-08-13 Subhash Gore Fenofibrate formulations
WO2009101616A1 (en) 2008-02-11 2009-08-20 Ramot At Tel Aviv University Ltd. Novel conjugates for treating neurodegenerative diseases and disorders
US20090221620A1 (en) 2008-02-20 2009-09-03 Celera Corporation Gentic polymorphisms associated with stroke, methods of detection and uses thereof
CA2716348C (en) 2008-02-21 2017-04-04 Sequoia Pharmaceuticals, Inc. Diamide inhibitors of cytochrome p450
WO2009108828A2 (en) * 2008-02-27 2009-09-03 Dr. Reddy's Laboratories Ltd. Solubility-enhanced forms of aprepitant and pharmaceutical compositions thereof
US9364443B2 (en) 2008-03-05 2016-06-14 Baxter International, Inc. Compositions and methods for drug delivery
US8404850B2 (en) * 2008-03-13 2013-03-26 Southwest Research Institute Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors
WO2009117401A2 (en) * 2008-03-21 2009-09-24 Elan Pharama International Limited Compositions for site-specific delivery of imatinib and methods of use
CA2756690C (en) 2008-03-28 2016-08-16 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
HU230862B1 (hu) * 2008-04-28 2018-10-29 DARHOLDING Vagyonkezelő Kft Berendezés és eljárás nanorészecskék folyamatos üzemű előállítására
US20110064816A1 (en) * 2008-05-13 2011-03-17 Dr. Reddy's Laboratories Ltd. Atorvastatin compositions
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CN104689432B (zh) 2008-06-13 2018-07-06 曼金德公司 干粉吸入器和用于药物输送的系统
GB2462022B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof
JP5479465B2 (ja) 2008-06-20 2014-04-23 マンカインド コーポレイション 吸入努力をリアルタイムにプロファイルする対話式機器および方法
EP2310525B1 (de) 2008-07-09 2014-02-26 Celera Corporation Mit herz-kreislauf-erkrankungen assoziierte genetische polymorphismen, nachweisverfahren und ihre verwendung
US20100151037A1 (en) * 2008-08-07 2010-06-17 Yivan Jiang Method for the preparation of nanoparticles containing a poorly water-soluble pharmaceutically active compound
DE102008037025C5 (de) 2008-08-08 2016-07-07 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
US8722706B2 (en) * 2008-08-15 2014-05-13 Southwest Research Institute Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts
ES2477884T3 (es) 2008-08-19 2014-07-18 Xenoport, Inc. Profármacos de hidrogenofumarato de metilo, composiciones farmacéuticas de los mismos y procedimientos de uso
US9700525B2 (en) 2008-08-20 2017-07-11 Board Of Supervisors Of Louisiana State University And Agricultural & Mechanical College Continuous local slow-release of therapeutics for head and neck problems and upper aerodigestive disorders
CA2749941C (en) 2008-09-10 2018-04-24 Biochemics, Inc. Ibuprofen for topical administration
TWI580441B (zh) * 2008-09-19 2017-05-01 愛爾康研究有限公司 穩定的藥學次微米懸浮液及其形成方法
CN102149410B (zh) * 2008-09-19 2014-05-14 株式会社活效制药 医疗用复合有机化合物粉体及其制造方法以及悬浮液
GB0818403D0 (en) * 2008-10-08 2008-11-12 Univ Leuven Kath Aqueous electrophoretic deposition
US8309134B2 (en) * 2008-10-03 2012-11-13 Southwest Research Institute Modified calcium phosphate nanoparticle formation
WO2010040648A2 (en) * 2008-10-06 2010-04-15 Katholieke Universiteit Leuven, K.U.Leuven R&D Functional layers of biomolecules and living cells, and a novel system to produce such
US20100098770A1 (en) * 2008-10-16 2010-04-22 Manikandan Ramalingam Sirolimus pharmaceutical formulations
US8277697B2 (en) * 2008-10-29 2012-10-02 Global Oled Technology Llc Color filter element with improved colorant dispersion
EP2370438A1 (de) 2008-12-04 2011-10-05 Exelixis, Inc. Imidazo[1,2a]pyridinverbindungen, ihre verwendung als s1p1-agonisten und verfahren zu ihrer herstellung
MX2011006307A (es) * 2008-12-15 2011-10-14 Banner Pharmacaps Inc Metodos para aumentar la liberacion y absorcion de agentes activos insolubles en agua.
ES2397934T3 (es) 2008-12-17 2013-03-12 Amgen Inc. Compuestos de aminopiridina y carboxipiridina como inhibidores de fosfodiesterasa 10
AU2009329872B2 (en) 2008-12-23 2016-07-07 Gilead Pharmasset Llc Synthesis of purine nucleosides
SG172361A1 (en) 2008-12-23 2011-07-28 Pharmasset Inc Nucleoside analogs
AR074897A1 (es) 2008-12-23 2011-02-23 Pharmasset Inc Fosforamidatos de nucleosidos
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US8501759B2 (en) 2009-01-02 2013-08-06 Fournier Laboratories Ireland Limited Use of fibrates
EP2385824A2 (de) 2009-01-06 2011-11-16 Pharmanova, Inc. Nanoteilchenförmige pharmazeutische formulierungen
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US20100183687A1 (en) * 2009-01-22 2010-07-22 Cox D Phillip Process for preparing particles of opioids and compositions produced thereby
AR075180A1 (es) * 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
CN102365098A (zh) 2009-01-30 2012-02-29 明治制果药业株式会社 细粉状药物组合物
CN102405044A (zh) 2009-02-06 2012-04-04 南加利福尼亚大学 含有单萜的治疗组合物
WO2010091104A1 (en) 2009-02-06 2010-08-12 Exelixis, Inc. Glucosylceramide synthase inhibitors
WO2010091164A1 (en) 2009-02-06 2010-08-12 Exelixis, Inc. Inhibitors of glucosylceramide synthase
US20100204265A1 (en) * 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
JP2012518037A (ja) 2009-02-18 2012-08-09 アムジエン・インコーポレーテツド ｍＴＯＲキナーゼ阻害剤としてのインドール／ベンゾイミダゾール化合物
DK2400950T3 (da) 2009-02-26 2019-07-29 Glaxo Group Ltd Farmaceutiske formuleringer omfattende 4-{(1 r)-2-[(6-{2-[(2,6-dichlorbenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
PL2405963T3 (pl) 2009-03-11 2014-04-30 Mannkind Corp Urządzenie, układ i sposób pomiaru oporu inhalatora
EP2411039A4 (de) 2009-03-23 2015-05-06 Brigham & Womens Hospital Glycokonjugat-impfstoffe
US7828996B1 (en) * 2009-03-27 2010-11-09 Abbott Cardiovascular Systems Inc. Method for the manufacture of stable, nano-sized particles
WO2010114770A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
WO2010117662A1 (en) 2009-03-30 2010-10-14 Exelixis, Inc. Modulators of s1p and methods of making and using
US20100260858A1 (en) * 2009-04-09 2010-10-14 Elan Pharma International Limited Drug delivery composition
US20100268187A1 (en) * 2009-04-17 2010-10-21 Ranbaxy Laboratories Limited Packaging for sirolimus and composition thereof
AU2010239081C1 (en) 2009-04-24 2014-11-06 Iceutica Pty Ltd A novel formulation of indomethacin
BRPI1014272A2 (pt) 2009-04-24 2016-10-18 Iceutica Pty Ltd nova formulação de diclofenac
US10952965B2 (en) * 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
US20100291221A1 (en) * 2009-05-15 2010-11-18 Robert Owen Cook Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
US9278070B2 (en) 2009-05-18 2016-03-08 Sigmoid Pharma Limited Composition comprising oil drops
EP2253306A1 (de) 2009-05-18 2010-11-24 Royal College of Surgeons in Ireland Orodispersible Dosierungsformen mit Festarzneimitteldispersionen
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
WO2010135714A2 (en) 2009-05-22 2010-11-25 The Methodist Hospital Research Institute Methods for modulating adipocyte expression using microrna compositions
WO2010135568A1 (en) 2009-05-22 2010-11-25 Exelixis, Inc. Benzoxazepines as inhibitors of mtor and their use to treat cancer
FR2945950A1 (fr) 2009-05-27 2010-12-03 Elan Pharma Int Ltd Compositions de nanoparticules anticancereuses et procedes pour les preparer
AU2010254180B2 (en) 2009-05-27 2015-08-27 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate active agent compositions
TR200904500A2 (tr) 2009-06-10 2009-10-21 Öner Levent Ezetimib nanokristallerinin hazırlanması için yöntem ve farmasötik formülasyonları.
KR20120042836A (ko) 2009-06-12 2012-05-03 아다지오 파마슈티컬즈 엘티디 설하 아포모르핀
EP2440184B1 (de) 2009-06-12 2023-04-05 MannKind Corporation Diketopiperazin-mikropartikel mit definierten spefiischen oberflächenbereichen
AU2010260208B2 (en) 2009-06-16 2014-11-13 Bristol-Myers Squibb Holdings Ireland Unlimited Company Dosage forms of apixaban
WO2011005496A2 (en) 2009-06-22 2011-01-13 Massachusetts Eye & Ear Infirmary Islet1 (isl1) and hearing loss
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
EP2451442A4 (de) 2009-07-09 2014-02-12 Oshadi Drug Administration Ltd Matrixträgerzusammensetzungen, verfahren und verwendungen
US20130029970A1 (en) 2009-07-10 2013-01-31 Ironwood Pharmaceuticals, Inc CB Receptor Agonists
EP2283824B1 (de) 2009-07-30 2017-04-19 Special Products Line S.p.A. Zusammensetzungen und Formulierungen, die auf quellbaren Matrizen basieren, zur verzögerten Freisetzung von schlecht löslichen Arzneimitteln, wie zum Beispiel Clarithromycin
AR077692A1 (es) 2009-08-06 2011-09-14 Vitae Pharmaceuticals Inc Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
GB2485327A (en) 2009-08-12 2012-05-09 Sigmoid Pharma Ltd Immunomodulatory compositions comprising a polymer matrix and an oil phase
EP2298296A1 (de) 2009-08-25 2011-03-23 CNRS Centre National De La Recherche Scientifique Zusammensetzung und Behandlung kognitiver Beeinträchtigungen bei Personen mit Down-Syndrom
ES2545794T3 (es) 2009-08-28 2015-09-15 Research Development Foundation Análogos de urocortina 2 y usos de los mismos
US9775819B2 (en) * 2009-09-16 2017-10-03 R.P. Scherer Technologies, Llc Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
AU2010249210B2 (en) * 2009-10-16 2016-04-07 Lifecare Innovations Pvt. Ltd. A novel formulation for treating fungal infection
EP2490679B8 (de) 2009-10-22 2022-10-26 Tpc-Api Llc Verfahren zur herstellung und verwendung von zusammensetzungen mit flavonoiden
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
AU2010315190A1 (en) 2009-11-05 2012-05-10 Lexicon Pharmaceuticals, Inc. Tryptophan hydroxylase inhibitors for the treatment of cancer
CA2780292A1 (en) * 2009-11-10 2011-05-19 Celgene Corporation Nanosus pens ion of a poorly soluble drug made by microfluidization process
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
US8921337B2 (en) 2009-12-03 2014-12-30 Alcon Research, Ltd. Carboxyvinyl polymer-containing nanoparticle suspensions
BR112012013639A2 (pt) * 2009-12-09 2017-04-04 Bar-Ilan Univ "métodos pára melhorar funções congnitivas"
EP2509960A1 (de) 2009-12-11 2012-10-17 Exelixis, Inc. Tgr5-agonisten
TW201132353A (en) 2009-12-18 2011-10-01 Amgen Inc WISE binding agents and epitopes
AU2010335655B2 (en) 2009-12-22 2015-03-05 Leo Pharma A/S Calcipotriol monohydrate nanocrystals
TW201130810A (en) 2009-12-23 2011-09-16 Ironwood Pharmaceuticals Inc CRTH2 modulators
HUE031184T2 (en) 2010-01-27 2017-06-28 Glaxosmithkline Biologicals Sa Modified tuberculosis antigens
US9028873B2 (en) * 2010-02-08 2015-05-12 Southwest Research Institute Nanoparticles for drug delivery to the central nervous system
US20130196960A1 (en) 2010-02-09 2013-08-01 Ironwood Pharmaceuticals, Inc. Cannabinoid Receptor Agonists
US20130178453A1 (en) 2010-02-09 2013-07-11 Ironwood Pharmaceuticals, Inc. Cannabinoid Agonists
US8901137B2 (en) 2010-02-09 2014-12-02 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors
AU2011215963A1 (en) 2010-02-10 2012-08-02 Lexicon Pharmaceuticals, Inc. Tryptophan hydroxylase inhibitors for the treatment of metastatic bone disease
CA2789711C (en) 2010-02-17 2014-08-05 Amgen Inc. Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
US8440651B2 (en) 2010-02-22 2013-05-14 F. Hoffmann-La Roche Ag Pyrido[3,2-d]pyrimidine PI3K delta inhibitor compounds and methods of use
WO2011104637A2 (en) * 2010-02-24 2011-09-01 Ramot At Tel-Aviv University Ltd. Crystalline forms of the tri-mesylate salt of perphenazine-gaba and process of producing the same
US9168504B2 (en) * 2010-03-11 2015-10-27 Hamamatsu Photonics K.K. Fine-particle dispersion liquid manufacturing method and fine-particle dispersion liquid manufacturing apparatus
CA2793241C (en) 2010-03-22 2020-07-14 Bio-Synectics Inc. Method for preparing nano-particles
WO2011123672A1 (en) 2010-03-31 2011-10-06 Pharmasset, Inc. Purine nucleoside phosphoramidate
EP2752422B1 (de) 2010-03-31 2017-08-16 Gilead Pharmasset LLC Stereoselektive synthese von phosphorhaltigen wirkstoffen
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
DE102010003711B4 (de) 2010-04-08 2015-04-09 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoffpartikel
US20110269735A1 (en) 2010-04-19 2011-11-03 Celera Corporation Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof
ES2711256T3 (es) 2010-04-23 2019-04-30 Univ Florida Composiciones de rAAV-guanilato ciclasa y métodos para tratar la amaurosis congénita de Leber 1 (LCA1)
WO2011135580A2 (en) 2010-04-28 2011-11-03 Cadila Healthcare Limited Pharmaceutical compositions of sirolimus
EP2566461A2 (de) * 2010-05-05 2013-03-13 Ratiopharm GmbH Festes tapentadol in nicht-kristalliner form
US8765737B1 (en) 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8362007B1 (en) 2010-05-11 2013-01-29 Demerx, Inc. Substituted noribogaine
US9394294B2 (en) 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
WO2011143129A1 (en) 2010-05-13 2011-11-17 Amgen Inc. Nitrogen- heterocyclic compounds as phosphodiesterase 10 inhibitors
EA201291236A1 (ru) 2010-05-13 2013-11-29 Эмджен Инк. Азотные гетероциклические соединения, применимые в качестве ингибиторов pde10
EP2569302A1 (de) 2010-05-13 2013-03-20 Amgen, Inc Heteroaryloxyheterocyclylverbindungen als pde10-hemmer
AU2011253058A1 (en) 2010-05-13 2012-12-06 Amgen Inc. Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors
EA027039B1 (ru) 2010-05-14 2017-06-30 Эмджен Инк. Композиции с высокой концентрацией антител
WO2011146583A2 (en) 2010-05-19 2011-11-24 Elan Pharma International Limited Nanoparticulate cinacalcet formulations
HUP1000325A2 (en) 2010-06-18 2012-01-30 Druggability Technologies Ip Holdco Jersey Ltd Nanostructured aprepitant compositions and process for their preparation
RU2571331C1 (ru) 2010-06-21 2015-12-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
US8637648B1 (en) 2010-06-22 2014-01-28 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
US8741891B1 (en) 2010-06-22 2014-06-03 Demerx, Inc. N-substituted noribogaine prodrugs
AU2011280039B2 (en) 2010-06-30 2014-08-07 Victoria Link Ltd Methods and compositions for treatment of multiple sclerosis
EA201390085A1 (ru) 2010-07-09 2013-06-28 Экселиксис, Инк. Композиции ингибиторов киназ для лечения рака
US20130216552A1 (en) 2010-07-12 2013-08-22 Ironwood Pharmaceuticals, Inc. Crth2 modulators
WO2012009134A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
MX2013000733A (es) 2010-07-23 2013-05-30 Demerx Inc Composiciones de noribogaina.
WO2012024616A1 (en) 2010-08-19 2012-02-23 Buck Institute For Age Research Methods of treating miild cognitive impairment (mci) and related discorders
CA2812091C (en) 2010-09-14 2020-03-24 Exelixis, Inc. Inhibitors of pi3k-delta and methods of their use and manufacture
WO2012037132A1 (en) 2010-09-14 2012-03-22 Exelixis, Inc. Phtalazine derivatives as jak1 inhibitors
US9670212B2 (en) 2010-09-14 2017-06-06 Exelixis, Inc. Inhibitors of PI3K-delta and methods of their use and manufacture
WO2012038963A1 (en) 2010-09-22 2012-03-29 Ramot At Tel-Aviv University Ltd. An acid addition salt of a nortriptyline-gaba conjugate and a process of preparing same
ES2616752T3 (es) 2010-09-23 2017-06-14 Nuformix Limited Composición y cocristal de aprepitant L-prolina
CA2812744A1 (en) 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
EA027476B1 (ru) 2010-09-27 2017-07-31 Экселиксис, Инк. Применение n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида для лечения кастрационно-резистентного рака простаты и остеобластических метастазов в кости
US20140066444A1 (en) 2010-09-27 2014-03-06 Exelixis, Inc. Method of Treating Cancer
US20150093440A1 (en) * 2010-10-15 2015-04-02 Glaxo Group Limited Aggregate nanoparticulate medicament formulations, manufacture and use thereof
US20120108651A1 (en) 2010-11-02 2012-05-03 Leiden University Medical Center (LUMC) Acting on Behalf of Academic Hospital Leiden (AZL) Genetic polymorphisms associated with venous thrombosis and statin response, methods of detection and uses thereof
AU2011323458B2 (en) * 2010-11-02 2017-02-23 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
WO2012061337A1 (en) 2010-11-02 2012-05-10 Exelixis, Inc. Fgfr2 modulators
WO2012065019A2 (en) 2010-11-12 2012-05-18 Exelixis, Inc. Pyridopyrimidinone inhibitors of p13k alpha
WO2012065057A2 (en) 2010-11-12 2012-05-18 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use
EP2640366A2 (de) 2010-11-15 2013-09-25 Exelixis, Inc. Benzoxazepine als pi3k/mtor-hemmer sowie verfahren zur ihrer verwendung und herstellung
US20140066431A1 (en) 2010-11-15 2014-03-06 Exelixis, Inc. Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture
US20140378436A9 (en) 2010-11-24 2014-12-25 Exelixis, Inc. Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their use and Manufacture
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
ES2716158T3 (es) 2010-11-30 2019-06-10 Gilead Pharmasset Llc 2'-spiro-nucleótidos para el tratamiento de hepatitis C
MX2013006467A (es) 2010-12-09 2013-10-01 Amgen Inc Compuestos biciclicos como inhibidores pim.
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
KR101890317B1 (ko) 2010-12-16 2018-08-22 선오비온 파마슈티컬스 인코포레이티드 설하 필름
EP2658857B1 (de) 2010-12-29 2016-11-02 Inhibitex, Inc. Substituierte purin-nukleoside, phosphoroamidate und phosphorodiamidatderivate zur behandlung von virusinfektionen
JP2014505052A (ja) 2011-01-06 2014-02-27 ベータ ファルマ カナダ インコーポレーテッド 癌の治療および予防用の新規なウレア
EP2481740B1 (de) 2011-01-26 2015-11-04 DemeRx, Inc. Verfahren und Zusammensetzungen zur Herstellung von Noribogain aus Voacangin
WO2012118903A2 (en) 2011-03-01 2012-09-07 Amgen Inc. Bispecific binding agents
JP2014510105A (ja) 2011-03-22 2014-04-24 アムジエン・インコーポレーテツド Ｐｉｍ阻害剤としてのアゾール化合物
CN103517920B (zh) 2011-03-25 2018-04-17 安进公司 抗硬化蛋白(sclerostin)抗体晶体及其制剂
DK2694402T3 (en) 2011-04-01 2017-07-03 Mannkind Corp BLISTER PACKAGE FOR PHARMACEUTICAL CYLINDER AMPULS
LT2696848T (lt) 2011-04-15 2020-09-10 Janssen Pharmaceutica N.V. Liofilizuotos vaisto nanosuspensijos
EP2701722A4 (de) 2011-04-28 2014-12-31 Univ Southern California Aus menschlichen myeloiden suppressorzellen gewonnene krebsmarker
MX2013012661A (es) 2011-04-29 2014-03-27 Amgen Inc Compuestos de piridazina biciclicos como inhibidores pim.
KR20140040726A (ko) 2011-04-29 2014-04-03 엑셀리시스, 인코포레이티드 PI3K/mTOR의 피리도피리미디논 억제제를 사용하는 림프종을 치료하는 방법
US9221760B2 (en) 2011-05-09 2015-12-29 Van Andel Research Institute Autophagy inhibitors
US8709034B2 (en) 2011-05-13 2014-04-29 Broncus Medical Inc. Methods and devices for diagnosing, monitoring, or treating medical conditions through an opening through an airway wall
EP2706940B1 (de) 2011-05-13 2016-12-14 Broncus Medical, Inc. Verfahren und vorrichtungen zur gewebeablation
PL2710005T3 (pl) 2011-05-17 2017-07-31 Principia Biopharma Inc. Inhibitory kinazy tyrozynowej
EP2710006A1 (de) 2011-05-17 2014-03-26 Principia Biopharma Inc. Azaindolderivate als tyrosinkinaseinhibitoren
US20140107151A1 (en) 2011-05-17 2014-04-17 Principia Biophama Inc. Tyrosine kinase inhibitors
US9376438B2 (en) 2011-05-17 2016-06-28 Principia Biopharma, Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
WO2012174158A2 (en) 2011-06-14 2012-12-20 Hale Biopharma Ventures, Llc Administration of benzodiazepine
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
WO2012177595A1 (en) 2011-06-21 2012-12-27 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
EP2727919B1 (de) 2011-06-28 2019-05-08 Fujian Mindong Rejuvenation Pharmaceutical Co., Ltd. Benzocycloheptanthiophenderivate für antiallergische reaktionen
ES2624984T3 (es) 2011-07-15 2017-07-18 Viiv Healthcare Uk Limited Derivados de ácido 2-(pirrolo[2,3-b]piridin-5-il)-2-(t-butoxi)-acético como inhibidores de la replicación del VIH para el tratamiento del SIDA
RU2607191C2 (ru) 2011-07-22 2017-01-10 Хемоцентрикс, Инк. Полиморфные формы натриевой соли 4-трет-бутил-n-[4-хлор-2-(1-окси-пиридин-4-карбонил)-фенил]-бензолсульфонамида
JP6122003B2 (ja) 2011-07-22 2017-04-26 ケモセントリックス， インコーポレイテッド ４−ｔｅｒｔ−ブチル−Ｎ−［４−クロロ−２−（１−オキシ−ピリジン−４−カルボニル）−フェニル］−ベンゼンスルホンアミドのナトリウム塩の結晶形
PT2739311T (pt) 2011-08-04 2018-03-26 Amgen Inc Método para tratamento de defeitos de lacunas ósseas
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
RS57644B1 (sr) 2011-09-01 2018-11-30 Glaxo Group Ltd Novi kristalni oblik
AU2012308414A1 (en) 2011-09-14 2014-05-01 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors for the treatment of cancer
KR101794032B1 (ko) 2011-09-21 2017-11-07 (주)바이오시네틱스 나노입자 제조방법
MX351133B (es) 2011-09-22 2017-10-03 Exelixis Inc Metodo para tratar osteoporosis.
WO2013043553A1 (en) 2011-09-22 2013-03-28 Glaxosmithkline Llc Pyrrolopyridinone compounds and methods for treating hiv
KR102180667B1 (ko) 2011-09-29 2020-11-20 피엘엑스 옵코 인코포레이티드 위장관을 따라 약물을 표적화 방출하기 위한 pH 감응성 담체, 그로부터의 조성물, 및 이들의 제조 및 사용 방법
WO2013056067A1 (en) 2011-10-13 2013-04-18 Exelixis, Inc. Compounds for use in the treatment of basal cell carcinoma
TWI580442B (zh) * 2011-10-19 2017-05-01 傑特大學 醫藥毫微懸浮物
AU2012328885B2 (en) 2011-10-24 2017-08-31 Mannkind Corporation Methods and compositions for treating pain
US20140303172A1 (en) 2011-11-01 2014-10-09 Exelixis, Inc. Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Lymphoproliferative Malignancies
WO2013067306A1 (en) 2011-11-02 2013-05-10 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors for the treatment of childhood cancers
JP2014532766A (ja) 2011-11-08 2014-12-08 エクセリクシス， インク． 癌を治療する、ｍｅｔ及びｖｅｇｆの二重阻害剤
CN104039226A (zh) 2011-11-08 2014-09-10 埃克塞里艾克西斯公司 定量癌症治疗的方法
BR112014011417B1 (pt) 2011-11-11 2021-10-13 Fred Hutchinson Cancer Research Center Polipeptídeo isolado capaz de elicitar uma resposta de célula t antígeno-específica para ciclina a1 humana, composição imunogênica compreendendo o referido polipeptídeo, bem como método para preparar células apresentadoras de antígeno, antígeno-pulsadas,e uso destas para superexpressão de ccna1
US9562015B2 (en) 2011-11-17 2017-02-07 The Regents Of The University Of Colorado, A Body Methods and compositions for enhanced drug delivery to the eye and extended delivery formulations
WO2013078235A1 (en) 2011-11-23 2013-05-30 Broncus Medical Inc Methods and devices for diagnosing, monitoring, or treating medical conditions through an opening through an airway wall
WO2013076659A1 (en) 2011-11-25 2013-05-30 Nuformix Limited Aprepitant l-proline solvates - compositions and cocrystals
EP2788003A4 (de) 2011-12-09 2015-05-27 Demerx Inc Phosphatester von noribogain
JO3387B1 (ar) 2011-12-16 2019-03-13 Glaxosmithkline Llc مشتقات بيتولين
EP2797953B1 (de) 2011-12-28 2020-06-03 Amgen Inc. Verfahren zur behandlung von alveolarknochenverlust durch verwendung von anti-sclerostin-antikörpern
US9150584B2 (en) 2012-01-25 2015-10-06 Demerx, Inc. Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
AU2013212139A1 (en) 2012-01-25 2014-06-26 Demerx, Inc. Synthetic voacangine
CA2863083C (en) 2012-01-26 2023-09-19 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
WO2013130660A1 (en) 2012-02-28 2013-09-06 Amgen Inc. Amides as pim inhibitors
TW201348231A (zh) 2012-02-29 2013-12-01 Amgen Inc 雜雙環化合物
LT3677252T (lt) 2012-03-19 2023-10-10 Cidara Therapeutics, Inc. Dozavimo režimas, skirtas echinokandino klasės junginiams
US9040091B2 (en) 2012-03-22 2015-05-26 Nanotherapeutics, Inc. Compositions and methods for oral delivery of encapsulated diethylenetriaminepentaacetate particles
KR101956586B1 (ko) * 2012-03-27 2019-03-11 일양약품주식회사 약제학적 조성물 및 이의 제조방법
WO2013148978A1 (en) 2012-03-30 2013-10-03 Lexicon Pharmaceuticals, Inc. Methods and compositions for the treatment of necrotizing enterocolitis
WO2013155422A1 (en) 2012-04-12 2013-10-17 Ironwood Pharmaceuticals, Inc. Methods of treating alopecia and acne
US9452107B2 (en) 2012-04-16 2016-09-27 New Jersey Institute Of Technology Systems and methods for superdisintegrant-based composite particles for dispersion and dissolution of agents
WO2013166296A1 (en) 2012-05-02 2013-11-07 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
JP6360039B2 (ja) 2012-05-03 2018-07-18 カラ ファーマシューティカルズ インコーポレイテッド 複数の被覆された粒子を含む組成物、医薬組成物、医薬製剤、及び当該粒子の形成方法
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
EP2844227B1 (de) 2012-05-03 2020-11-18 Kala Pharmaceuticals, Inc. Pharmazeutische nanopartikel mit verbessertem mukosalem transport
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
IN2014MN02002A (de) 2012-05-11 2015-08-07 Activus Pharma Co Ltd
BR112014028622A2 (pt) 2012-05-17 2017-06-27 Transtech Pharma Llc composições de ativador de glucoquinase para o tratamento de diabetes
NZ702548A (en) 2012-06-04 2015-11-27 Pharmacyclics Llc Crystalline forms of a bruton’s tyrosine kinase inhibitor
UY34858A (es) 2012-06-14 2013-11-29 Amgen Inc Compuestos de azetidina y piperidina útiles como inhibidores de pde10
CN110123763A (zh) 2012-06-21 2019-08-16 法斯瑞斯公司 靛玉红的奈米粒子、其衍生物以及制造和使用所述奈米粒子的方法
AU2013285488B2 (en) 2012-07-05 2018-03-22 Ucb Pharma S.A. Treatment for bone diseases
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
AU2013289957B2 (en) 2012-07-12 2017-02-23 Mannkind Corporation Dry powder drug delivery systems and methods
ES2647437T3 (es) 2012-07-12 2017-12-21 Viiv Healthcare Uk Limited Compuestos y procedimientos para tratar el VIH
JOP20130213B1 (ar) 2012-07-17 2021-08-17 Takeda Pharmaceuticals Co معارضات لمستقبلht3-5
WO2014022752A1 (en) 2012-08-03 2014-02-06 Amgen Inc. Macrocycles as pim inhibitors
EP2882722B1 (de) 2012-08-13 2016-07-27 Takeda Pharmaceutical Company Limited Chinoxalinderivate als gpr6-modulatoren
CA2882713A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
CA2882730C (en) 2012-08-22 2019-12-31 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
WO2014031178A1 (en) 2012-08-24 2014-02-27 Etubics Corporation Replication defective adenovirus vector in vaccination
JP2015526520A (ja) 2012-08-31 2015-09-10 プリンシピア バイオファーマ インコーポレイテッド Ｉｔｋ阻害剤としてのベンズイミダゾール誘導体
WO2014036528A2 (en) 2012-08-31 2014-03-06 Ixchel Pharma, Llc Agents useful for treating obesity, diabetes and related disorders
ES2731833T3 (es) 2012-09-10 2019-11-19 Principia Biopharma Inc Compuestos pirazolopirimidínicos comos inhibidores de cinasas
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
JP2016500076A (ja) 2012-11-20 2016-01-07 プリンシピア バイオファーマ インコーポレイテッド Ｊａｋ３阻害剤としてのアザインドール誘導体
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
JP6382831B2 (ja) 2012-11-30 2018-08-29 サンフォード−バーンハム メディカル リサーチ インスティテュート アポトーシス阻害タンパク質（ｉａｐ）のアンタゴニスト
WO2014091318A1 (en) 2012-12-11 2014-06-19 Lupin Atlantis Holdings, S.A. Reduced dose pharmaceutical compositions of fenofibrate
WO2014100021A1 (en) 2012-12-17 2014-06-26 Exelixis, Inc. Tgr5 agonists: imidazole and triazole compounds containing a quaternary nitrogen
US8940728B2 (en) 2012-12-20 2015-01-27 Demerx, Inc. Substituted noribogaine
JP2016508979A (ja) 2012-12-20 2016-03-24 デメレックス， インコーポレイテッド 置換ノルイボガイン
US9045481B2 (en) 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
MX2015009901A (es) 2013-02-01 2016-04-06 Santa Maria Biotherapeutics Inc Administración de un compuesto de antiactivina a a un sujeto.
CN105121023B (zh) * 2013-02-28 2017-08-25 太阳化学公司 用于在液体分散液中制造研磨的固体的装置和连续方法
AU2014226290B2 (en) * 2013-03-04 2018-11-15 Vtv Therapeutics Llc Stable glucokinase activator compositions
WO2014160177A2 (en) 2013-03-13 2014-10-02 Exelixis, Inc. Quinazoline inhibitors of pi3k
US9732068B1 (en) 2013-03-15 2017-08-15 GenSyn Technologies, Inc. System for crystalizing chemical compounds and methodologies for utilizing the same
EP3587404B1 (de) 2013-03-15 2022-07-13 MannKind Corporation Mikrokristalline diketopiperazinzusammensetzungen, verfahren zur herstellung und deren verwendung
BR112015023502A2 (pt) 2013-03-15 2017-07-18 Glaxosmithkline Biologicals Sa composição, e, métodos para intensificar uma resposta imune e melhorar ou prevenir substancialmente uma doença infecciosa, uma doença autoimune, ou uma condição alérgica em um indivíduo
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
PT2981271T (pt) 2013-04-05 2019-02-19 Boehringer Ingelheim Int Utilizações terapêuticas de empagliflozina
CN113181161A (zh) 2013-04-18 2021-07-30 勃林格殷格翰国际有限公司 药物组合物、治疗方法及其用途
EP2994470B1 (de) 2013-05-09 2018-04-18 Principia Biopharma Inc. Pyrido[2,3-d]pyrimidin-derivate als inhibitoren des fibroblastenwachstumsfaktors
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
WO2014203210A1 (en) 2013-06-20 2014-12-24 Glenmark Pharmaceuticals S.A. Nanoparticulate formulation comprising a trpa1 antagonist
WO2014205392A1 (en) 2013-06-21 2014-12-24 Xenoport, Inc. Cocrystals of dimethyl fumarate
BR112016000937A8 (pt) 2013-07-18 2021-06-22 Mannkind Corp formulações farmacêuticas de pó seco, método para a fabricação de uma formulação de pó seco e uso de uma formulação farmacêutica de pó seco
JP2016530930A (ja) 2013-08-05 2016-10-06 マンカインド コーポレイション 通気装置及び方法
TW201516020A (zh) 2013-09-06 2015-05-01 Xenoport Inc （ｎ，ｎ－二乙基胺甲醯基）甲基（２ｅ）丁－２－烯－１，４－二酸甲酯之晶形、合成方法及用途
WO2015042294A1 (en) 2013-09-18 2015-03-26 Xenoport, Inc. Nanoparticle compositions of dimethyl fumarate
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
EP2878311A1 (de) 2013-11-27 2015-06-03 Freund Pharmatec Ltd. Verbesserung der Löslichkeit für hydrophobe Wirkstoffe
JP6510539B2 (ja) 2014-01-09 2019-05-08 ザ ジェイ． デヴィッド グラッドストーン インスティテューツ， ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ． デヴィッド グラッドストーン 置換ベンゾオキサジン及び関連化合物
WO2015108945A2 (en) 2014-01-14 2015-07-23 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
WO2015108783A1 (en) 2014-01-16 2015-07-23 The Brigham And Women's Hospital, Inc. Targeted delivery of immunoregulatory drugs
SG11201606858RA (en) 2014-02-21 2016-09-29 Principia Biopharma Inc Salts and solid form of a btk inhibitor
WO2015134210A1 (en) 2014-03-03 2015-09-11 Principia Biopharma, Inc. BENZIMIDAZOLE DERIVATIVES AS RLK and ITK INHIBITORS
WO2015134608A1 (en) 2014-03-05 2015-09-11 Nanotherapeutics, Inc. Compositions and methods for oral delivery of encapsulated 3-aminopyridine-2-carboxaldehyde particles
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
ES2874875T3 (es) 2014-04-25 2021-11-05 Exelixis Inc Procedimiento de tratamiento de adenocarcinoma de pulmón
CA2948441A1 (en) 2014-05-12 2015-11-19 Glaxosmithkline Intellectual Property (No. 2) Limited Pharmaceutical compositions for treating infectious diseases
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
WO2015195673A2 (en) 2014-06-18 2015-12-23 Demerx, Inc. Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them
WO2015195950A1 (en) 2014-06-20 2015-12-23 Principia Biophamram Inc. Lmp7 inhibitors
EA032017B1 (ru) 2014-06-25 2019-03-29 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Кристаллические соли (s)-6-((1-ацетилпиперидин-4-ил)амино)-n-(3-(3,4-дигидроизохинолин-2(1h)-ил)-2-гидроксипропил)пиримидин-4-карбоксамида
DK3174535T3 (da) * 2014-08-01 2019-05-13 Glenmark Pharmaceuticals Sa Nanopartikelformulering, der omfatter en mpges-1-hæmmer
MX371417B (es) * 2014-08-18 2020-01-29 Alkermes Pharma Ireland Ltd Composiciones de profarmacos de aripiprazol.
US10016415B2 (en) 2014-08-18 2018-07-10 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
SG10201902499VA (en) 2014-09-03 2019-04-29 Genesegues Inc Therapeutic nanoparticles and related compositions, methods and systems
WO2016038519A1 (en) 2014-09-08 2016-03-17 Glaxosmithkline Intellectual Property Development Limited Crystalline forms of 2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophenyl)-n-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)acetamide
ES2883295T3 (es) 2014-09-29 2021-12-07 Takeda Pharmaceuticals Co Forma cristalina de 1-(1-metil-1h-pirazol-4-il)-n-((1r,5s,7s)-9-metil-3-oxa-9-azabiciclo[3.3.1]nonan-7-il)-1h-indol-3-carboxamida
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
EP3203995A4 (de) 2014-10-09 2019-05-15 Board of Regents of the University of Nebraska Zusammensetzungen und verfahren zur abgabe von therapiemitteln
KR20170102223A (ko) 2014-11-07 2017-09-08 시그모이드 파마 리미티드 사이클로스포린을 포함하는 조성물
EP3223796B1 (de) * 2014-11-25 2021-07-21 Curadigm Sas Pharmazeutische zusammensetzung, herstellung und verwendungen davon
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
US10695417B2 (en) 2015-01-09 2020-06-30 Etubics Corporation Human adenovirus serotype 5 vectors containing E1 and E2B deletions encoding the ebola virus glycoprotein
CN104587457B (zh) * 2015-01-13 2017-03-22 广东海大畜牧兽医研究院有限公司 一种利用难溶或不溶蛋白、多肽抗原制备纳米微粒疫苗的方法
US10166197B2 (en) 2015-02-13 2019-01-01 St. John's University Sugar ester nanoparticle stabilizers
US10022328B2 (en) 2015-02-20 2018-07-17 Cytec Industries Inc. Dialkyl sulfosuccinate compositions, method of making, and method of use
BR122023020985A2 (pt) 2015-03-03 2023-12-26 Pharmacyclics Llc Formulação de comprimido sólido de um inibidor de tirosina quinase de bruton
US20180071376A1 (en) 2015-03-23 2018-03-15 The Brigham And Women`S Hospital, Inc. Tolerogenic nanoparticles for treating diabetes mellitus
CA3019769C (en) 2015-04-21 2021-10-12 Sunovion Pharmaceuticals Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
CA2985652C (en) 2015-05-14 2020-03-10 Gerald W. FISHER Rapid methods for the extraction of nucleic acids from biological samples
EP3298011B1 (de) 2015-05-22 2021-11-17 Principia Biopharma Inc. Chinolonderivate als fibroblasten-wachstumsfaktorrezeptorinhibitoren
HUE055419T2 (hu) 2015-06-03 2021-11-29 Principia Biopharma Inc Tirozinkináz-inhibitorok
US20180305350A1 (en) 2015-06-24 2018-10-25 Principia Biopharma Inc. Tyrosine kinase inhibitors
WO2017004610A1 (en) 2015-07-02 2017-01-05 Exelixis, Inc. Tercyclic s1p3-sparing, s1p1 receptor agonists
WO2017004609A1 (en) 2015-07-02 2017-01-05 Exelixis, Inc. Thiadiazole modulators of s1p and methods of making and using
WO2017002078A1 (en) 2015-07-02 2017-01-05 Glaxosmithkline Intellectual Property Development Limited Inhibitors of indoleamine 2,3-dioxygenase
WO2017004608A1 (en) 2015-07-02 2017-01-05 Exelixis, Inc. Oxadiazole modulators of s1p methods of making and using
BR112018001537A2 (pt) 2015-07-28 2018-09-18 Glaxosmithkline Ip No 2 Ltd composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para tratamento e para prevenção de uma infecção por hiv em um indivíduo, e, uso de um composto ou sal
EP3328876A1 (de) 2015-07-28 2018-06-06 Glaxosmithkline Intellectual Property (No. 2) Limited Betuin-derivate zur prävention oder behandlung von hiv-infektionen
JP6775010B2 (ja) 2015-09-24 2020-10-28 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ インドールアミン２，３−ジオキシゲナーゼのモジュレーター
US20180273579A1 (en) 2015-09-24 2018-09-27 Glaxosmithkline Intellectual Property (No.2) Limited Compounds with hiv maturation inhibitory activity
CA2998827A1 (en) 2015-09-24 2017-03-30 Glaxosmithkline Intellectual Property (No.2) Limited Modulators of indoleamine 2,3-dioxygenase
KR20180082457A (ko) 2015-10-16 2018-07-18 마리누스 파마슈티컬스 인코포레이티드 나노입자들을 포함하는 주사용 뉴로스테로이드 제제들
US10583140B2 (en) 2016-01-27 2020-03-10 Glaxosmithkline Intellectual Property Development Limited Ingenol analogs, pharmaceutical compositions and methods of use thereof
ES2883450T3 (es) 2016-02-17 2021-12-07 Global Blood Therapeutics Inc Inhibidores de histona metiltransferasa
ES2893973T3 (es) 2016-02-17 2022-02-10 Alkermes Pharma Ireland Ltd Composiciones de múltiples profármacos de aripiprazol
US10590084B2 (en) 2016-03-09 2020-03-17 Blade Therapeutics, Inc. Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
CA2972296A1 (en) 2016-06-30 2017-12-30 Durect Corporation Depot formulations
TW201811376A (zh) 2016-07-01 2018-04-01 英商葛蘭素史密斯克藍智慧財產權有限公司 抗體-藥物結合物及使用其之治療方法
AU2017292646A1 (en) 2016-07-05 2019-02-07 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
JP2019524816A (ja) 2016-08-11 2019-09-05 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． てんかん性障害の処置のための方法および組成物
AU2017311636B2 (en) 2016-08-19 2023-08-10 Orasis Pharmaceuticals Ltd. Ophthalmic pharmaceutical compositions and uses relating thereto
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
CA3041033A1 (en) 2016-09-12 2018-03-15 Numerate, Inc. Monocyclic compounds useful as gpr120 modulators
EP4000634A1 (de) 2016-09-13 2022-05-25 Kyowa Kirin Co., Ltd. Tivozanib-haltige medizinische zusammensetzung
EP3523294A4 (de) 2016-09-28 2021-01-13 Blade Therapeutics, Inc. Calpain-modulatoren und therapeutische verwendungen davon
KR20190066044A (ko) * 2016-10-11 2019-06-12 디에스엠 아이피 어셋츠 비.브이. 나노-크기의 uv 흡수제의 제조
JP2020503269A (ja) 2016-11-28 2020-01-30 リポカイン インコーポレーテッド 経口ウンデカン酸テストステロン療法
CN110545669A (zh) 2016-12-16 2019-12-06 科佩斯性能化学股份有限公司 木材防腐剂及其生产方法
EP3558971B1 (de) 2016-12-22 2022-02-23 Global Blood Therapeutics, Inc. Histonmethyltransferaseaseinhibitoren
PL3571208T3 (pl) 2017-01-18 2021-09-20 Principia Biopharma Inc. Inhibitory immunoproteasomu
EP3609884A4 (de) 2017-04-10 2021-01-06 Sierra Oncology, Inc. Chk1 (sra737)/papi-kombinationsverfahren zur hemmung des tumorwachstums
WO2018191418A1 (en) 2017-04-11 2018-10-18 Saje Pharma, Llc Carbazole compounds and methods of use thereof
CN109152745A (zh) 2017-04-21 2019-01-04 株式会社生物研究 利用脂质作为研磨工序中的润滑剂的制备活性物质纳米粒子的方法
WO2018226998A1 (en) 2017-06-09 2018-12-13 Global Blood Therapeutics, Inc. Azaindole compounds as histone methyltransferase inhibitors
DK3651736T3 (da) 2017-07-14 2021-09-27 Janssen Pharmaceutica Nv Langtidsvirkende formuleringer
US11584734B2 (en) 2017-08-15 2023-02-21 Global Blood Therapeutics, Inc. Tricyclic compounds as histone methyltransferase inhibitors
CN111372927A (zh) 2017-08-15 2020-07-03 全球血液疗法股份有限公司 作为组蛋白甲基转移酶抑制剂的三环化合物
US11274102B2 (en) 2017-10-30 2022-03-15 Glaxosmithkline Intellectual Property Development Limited Compounds useful in HIV therapy
CA3080949C (en) 2017-11-16 2024-04-16 Principia Biopharma Inc. Immunoproteasome inhibitors
ES2928787T3 (es) 2017-11-16 2022-11-22 Principia Biopharma Inc Inhibidores del inmunoproteasoma
WO2019140365A1 (en) 2018-01-12 2019-07-18 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
WO2019169029A1 (en) 2018-02-28 2019-09-06 Bioxiness Pharmaceuticals, Inc. Target specific chemotherapeutic agents
WO2019169017A1 (en) 2018-02-28 2019-09-06 Bioxiness Pharmaceuticals, Inc. Chemotherapeutic agents
EP3762104A2 (de) * 2018-03-07 2021-01-13 ST IP Holding AG Kombinationszusammensetzungen und therapien mit 4-methyl-5-(pyrazin-2-yl)-3h-1,2-dithiol-3-thion sowie verfahren zur herstellung und verwendung davon
US20200407393A1 (en) 2018-03-07 2020-12-31 Glaxosmithkline Intellectual Property (No. 2) Limited Medical Use
KR20200138254A (ko) 2018-03-30 2020-12-09 암젠 인크 C-말단 항체 변이체
CA3132832A1 (en) 2018-04-09 2019-10-17 Howard E. Gendelman Antiviral prodrugs and formulations thereof
EP3804720A4 (de) 2018-06-11 2022-02-09 Otsuka Pharmaceutical Co., Ltd. Delamanid enthaltende zusammensetzung
WO2019241089A1 (en) 2018-06-12 2019-12-19 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
CN112789085A (zh) 2018-08-09 2021-05-11 葛兰素史克知识产权第二有限公司 可用于hiv疗法的化合物
US20210323993A1 (en) 2018-08-30 2021-10-21 Glaxosmithkline Intellectual Property (No. 2) Limited Compounds Useful in HIV Therapy
WO2020121006A2 (en) 2018-10-19 2020-06-18 Innostudio Inc. Method and apparatus to produce nanoparticles in an ostwald ripening flow device with tubes of variable path length
MX2021006156A (es) 2018-11-30 2021-09-08 Glaxosmithkline Ip Dev Ltd Compuestos utiles en la terapia para el vih.
WO2020118142A1 (en) 2018-12-07 2020-06-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of pospartum depression
MA54940A (fr) 2019-01-22 2021-12-22 The Roskamp Inst Dérivés d'acides aminés pour le traitement de maladies inflammatoires
SG11202108560RA (en) 2019-02-13 2021-09-29 Brigham & Womens Hospital Inc Anti-peripheral lymph node addressin antibodies and uses thereof
CR20210460A (es) 2019-03-06 2022-02-03 Glaxosmithkline Ip No 2 Ltd Compuestos útiles en la terapia del vih
EP4249070A3 (de) 2019-04-12 2024-04-17 Riboscience LLC Bicyclische heteroarylderivate als ectonukleotid-pyrophosphatase-phosphodiesterase-1-inhibitoren
WO2021026124A1 (en) 2019-08-05 2021-02-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treatment of status epilepticus
EP4010349A1 (de) 2019-08-08 2022-06-15 GlaxoSmithKline Intellectual Property (No. 2) Limited 4'-ethynyl-2'-deoxyadenosinderivate und ihre verwendung in der hiv-therapie
WO2021038509A1 (en) 2019-08-28 2021-03-04 Glaxosmithkline Intellectual Property (No.2) Limited 4'-ethynyl-2'-deoxyadenosine derivatives and their use in hiv therapy
CA3154437A1 (en) 2019-10-11 2021-04-15 Corbus Pharmaceuticals, Inc. Compositions of ajulemic acid and uses thereof
KR20220134529A (ko) 2019-12-06 2022-10-05 마리누스 파마슈티컬스 인코포레이티드 복합 결절성 경화증의 치료에 사용하기 위한 가낙솔론
WO2021150476A1 (en) 2020-01-20 2021-07-29 Genzyme Corporation Therapeutic tyrosine kinase inhibitors for relapsing multiple sclerosis (rms)
CA3172595A1 (en) 2020-03-26 2021-09-30 Ronald Zimmerman Pharmaceutical carriers capable of ph dependent reconstitution and methods for making and using same
TW202203934A (zh) 2020-04-17 2022-02-01 美商健臻公司 治療涉及全身過度發炎性反應的病症的受體相互作用蛋白激酶抑制劑
BR112022020974A2 (pt) 2020-04-22 2022-12-06 Principia Biopharma Inc Tratamento da síndrome da angústia respiratória aguda e outros distúrbios envolvendo tempestade de citocina usando inibidores de btk
EP3928772A1 (de) 2020-06-26 2021-12-29 Algiax Pharmaceuticals GmbH Nanopartikuläre zusammensetzung
MX2023000439A (es) 2020-07-09 2023-02-09 Janssen Pharmaceutica Nv Formulaciones a largo plazo.
WO2022008644A1 (en) 2020-07-09 2022-01-13 Janssen Pharmaceutica Nv Long-acting formulations
JP2023532982A (ja) 2020-07-09 2023-08-01 ヤンセン ファーマシューティカ エヌ．ベー． 長時間作用型配合物
CN112451520B (zh) * 2020-12-31 2021-10-15 江苏宇锐医药科技有限公司 一种缬沙坦氨氯地平组合物及其制备方法
EP4298105A1 (de) 2021-02-23 2024-01-03 VIIV Healthcare Company Verbindungen zur hiv-behandlung
WO2023023473A1 (en) 2021-08-16 2023-02-23 Sierra Oncology, Inc. Methods of using momelotinib to treat chronic kidney disease
CA3230398A1 (en) * 2021-08-31 2023-03-09 Natsar Pharmaceuticals, Inc. Intravenous formulations of rk-33
WO2023239727A1 (en) 2022-06-06 2023-12-14 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Lats inhibitors and uses thereof
WO2023244672A1 (en) 2022-06-14 2023-12-21 Assembly Biosciences, Inc. 2-(imidazo[1, 2-a]1,8-naphthyridin-8-yl)-1,3,4-oxadiazole derivatives as enhancers of innate immune response for the treatment of viral infections
WO2024006406A1 (en) 2022-06-30 2024-01-04 Genzyme Corporation Therapeutic tyrosine kinase inhibitors for multiple sclerosis and myasthenia gravis
WO2024010782A1 (en) 2022-07-06 2024-01-11 Vividion Therapeutics, Inc. Pharmaceutical compositions comprising wrn helicase inhibitors
WO2024010784A1 (en) 2022-07-06 2024-01-11 Vividion Therapeutics, Inc. Pharmaceutical compositions comprising wrn helicase inhibitors
WO2024068699A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
WO2024068693A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
WO2024081168A1 (en) 2022-10-11 2024-04-18 Genzyme Corporation Therapeutic tyrosine kinase inhibitors for multiple sclerosis
CN115844821A (zh) * 2023-01-03 2023-03-28 江苏知原药业股份有限公司 一种地奈德纳米晶混悬液、制备方法及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2671750A (en) * 1950-09-19 1954-03-09 Merck & Co Inc Stable noncaking aqueous suspension of cortisone acetate and method of preparing the same
US3192118A (en) * 1964-04-23 1965-06-29 Fmc Corp Cellulose crystallites radiopaque media
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
DK143689C (da) * 1975-03-20 1982-03-15 J Kreuter Fremgangsmaade til fremstilling af en adsorberet vaccine
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
SE8204244L (sv) * 1982-07-09 1984-01-10 Ulf Schroder Kristalliserad kolhydratsmatris for biologiskt aktiva substanser
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4663364A (en) * 1984-09-05 1987-05-05 Kao Corporation Biocidal fine powder, its manufacturing method and a suspension for agricultural use containing the above powder
GB8601100D0 (en) * 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
NL194638C (nl) * 1986-12-19 2002-10-04 Novartis Ag Hydrosol die vaste deeltjes van een farmaceutisch actieve stof bevat en farmaceutisch preparaat dat deze hydrosol bevat.
DE3722837A1 (de) * 1987-07-10 1989-01-19 Ruetgerswerke Ag Ophthalmisches depotpraeparat
JP2773895B2 (ja) * 1989-04-25 1998-07-09 東京田辺製薬株式会社 ダナゾール組成物
SE464743B (sv) * 1989-06-21 1991-06-10 Ytkemiska Inst Foerfarande foer framstaellning av laekemedelspartiklar
JP2642486B2 (ja) * 1989-08-04 1997-08-20 田辺製薬株式会社 難溶性薬物の超微粒子化法
FR2660556B1 (fr) * 1990-04-06 1994-09-16 Rhone Poulenc Sante Microspheres, leur procede de preparation et leur utilisation.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102018103528A1 (de) 2018-02-16 2019-08-22 Friedrich-Alexander-Universität Erlangen-Nürnberg Suspension nanoskaliger, organischer Partikel und Verfahren zu ihrer Herstellung
WO2019158509A1 (de) 2018-02-16 2019-08-22 Friedrich-Alexander-Universität Erlangen-Nürnberg Suspension nanoskaliger, organischer partikel und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
FI108333B (fi) 2002-01-15
HU9200226D0 (en) 1992-04-28
EP0499299A3 (en) 1993-03-03
FI920321A0 (fi) 1992-01-24
EP0499299B1 (de) 2000-08-16
ES2149164T3 (es) 2000-11-01
NZ241362A (en) 1993-06-25
NO920334L (no) 1992-07-27
NO920334D0 (no) 1992-01-24
ATE195416T1 (de) 2000-09-15
GR3034759T3 (en) 2001-02-28
HU221586B (hu) 2002-11-28
DE69231345D1 (de) 2000-09-21
RU2066553C1 (ru) 1996-09-20
JP3602546B2 (ja) 2004-12-15
MY108134A (en) 1996-08-15
MX9200291A (es) 1992-10-01
AU1014792A (en) 1992-07-30
NO303668B1 (no) 1998-08-17
DK0499299T3 (da) 2001-01-02
SG55104A1 (en) 1998-12-21
KR100200061B1 (ko) 1999-06-15
IL100754A0 (en) 1992-09-06
TW247275B (de) 1995-05-11
CA2059432A1 (en) 1992-07-26
EP0499299A2 (de) 1992-08-19
IE920217A1 (en) 1992-07-29
AU654836B2 (en) 1994-11-24
JPH04295420A (ja) 1992-10-20
CA2059432C (en) 2003-03-18
PT499299E (pt) 2001-01-31
HUT62462A (en) 1993-05-28
US5145684A (en) 1992-09-08
IL100754A (en) 1996-10-16
KR920014468A (ko) 1992-08-25
FI920321A (fi) 1992-07-26

Similar Documents

Publication Publication Date Title
ATE195416T1 (de) Oberflächenmodifizierte arzneimittel-nanopartikel
DK0577215T3 (da) Fremgangsmåde til fremstilling af overflademodificerede anticancer-nanopartikler
DE69309056D1 (de) Oberflaechenmodifizierte nsaid nanopartikeln
FI905588A0 (fi) Foerfarande foer behandling eller belaeggning av ett substrat med en vattenhaltig komposition och anvaendning av saodana kompositioner.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8331 Complete revocation